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Abstract
VEGF treatment during status epilepticus alters long-term hippocampal astrocyte morphology:
A detailed description of astrocyte morphology and glutamate transporter patterns with and
without administration of VEGF and seizure induction

by
Janice Rene Lenzer
Advisor: Susan D. Croll
VEGF treatment during pilocarpine-induced status epilepticus (SE) causes enduring preservation
of behavioral function in rats in the absence of enduring neuroprotection (Nicoletti et al., 2010).
In addition, VEGF treatment reduces hyperexcitability in hippocampal slices without altering
neuronal membrane properties (McCloskey et al, 2005). Combined, these data suggest the
possibility that other cells or mechanisms could be involved in the beneficial effects of VEGF
during SE. Our laboratory is interested in the potential contribution of astrocytes to these effects.
Astrocytes are not only reported to contribute to epileptiform discharges in the hippocampus
(Tian et al., 2005; Kang et al., 2005) but also to express VEGF receptors (Krum & Rosenstein,
2002). We previously reported that VEGF treatment significantly alters multiple astrocyte
parameters such as cell soma size, branching complexity, branch volume, number of dendrites,
nodes counts and highest order branching after SE. The current study investigated both astrocyte
morphology and glutamate transporter expression one month after SE in animals treated with
VEGF or inactivated VEGF during SE. Individual GFAP-immunostained astrocytes from both
CA1 and the dentate gyrus hilus were traced using Neurolucida software (Microbrightfield Inc.),
allowing morphological parameters to be analyzed via Branched Structure and Sholl analyses. In
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addition, Image J software was used to measure optical density in GLT1 (glial glutamate
transporter 1)-immunostained sections. VEGF treatment during SE significantly prevented postSE increases in number of branch intersections, process length, and node count. Furthermore, an
analysis of the distance to the nearest neighboring astrocyte revealed that VEGF treatment
significantly increased inter-astrocyte distance. GLT1 immunoreactivity in VEGF treated
animals was decreased compared to seized controls. VEGF treatment did not significantly alter
the shape of the astrocytes but rather the branching complexity and size. Because cell
morphology impacts cell physiology, it is possible that VEGF’s enduring effects on post-SE
astrocyte morphology impacts the functioning of the post-seizure hippocampus.
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Chapter 1: Introduction
Epilepsy
Epilepsy affects millions of people in the United States and around the world. It is comprised of
a group of disorders, known as the “epilepsies”, and is characterized by periodic, recurrent
spontaneous seizures. The epilepsies are among the most common neurological disorders for
which there is no known cure, and they can lead to multiple debilitating impairments.
The many types of seizures can be broadly categorized as generalized or partial seizures,
with this classification determined by the origin of electrical signaling. Generalized seizures
result from electrical activity of the entire brain, and are usually associated with a loss of
consciousness. Partial seizures are characterized by smaller initial foci and less common
impairment in consciousness. Where the seizure begins or originates can be of great importance
when considering treatments for individuals with epilepsy.
Partial and generalized seizures can also be classified as idiopathic, symptomatic or
cryptogenic based on etiology. Idiopathic seizures typically have either a genetic cause or are
spontaneous with no identified cause, such as chemical imbalances, and result from abnormal
neurotransmission. Typically there are no structural or functional abnormalities associated with
idiopathic epilepsy. A few examples of idiopathic seizures are Juvenile Myoclonic Epilepsy and
Childhood Absence Epilepsy under the classification of generalized seizures and Benign Focal
Childhood Epilepsy under the classification of partial seizures. In symptomatic epilepsy, on the
other hand, the cause has been identified; or if the cause is unknown but believed to be likely, the
epilepsy is referred to as Cryptogenic. A few examples of symptomatic epilepsy are West
Syndrome and Lennox-Gastaut Syndrome under the classification of generalized seizures and
Temporal Lobe Epilepsy or Frontal Lobe Epilepsy under the classification of partial seizures.
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Symptomatic epilepsy is associated with structural and functional abnormalities that in some
cases stem from a known cause such as traumatic brain injury (TBI) or are believed to result
from another problem such as Cerebral Palsy or Rett’s Syndrome.
One type of partial seizure, and the most common form of partial epilepsy is temporal
lobe epilepsy (TLE). TLE patients are also the most likely to be eligible for surgical resectioning.
However, this surgery is not successful for many who undergo the procedure. Despite the
common feature of seizures originating in the temporal lobe, particularly the hippocampus and
other limbic structures, the underlying mechanisms of pathology are varied and include, but are
not limited to, trauma, tumors, vascular malformations and hippocampal sclerosis. There is high
variability among the epilepsies from individual to individual and one advantage of TLE is that
there appears to be similar patterns or trends that are observed across individuals. This
characteristic makes TLE a prime candidate for investigation and for the development of animal
models to address epilepsy treatment (Edward Bertram, 2009). TLE is associated with both
simple and complex partial seizures and is likely to be the most common form of epilepsy
because the temporal lobes appear to be the most epileptogenic region of the brain. In human
patients, 90% of those with temporal epileptiform abnormalities have a history of seizures
(David Ko, 2012 Medscape).
Individuals diagnosed with epilepsy, especially TLE, typically experience
neuroanatomical and neurophysiological changes at both the cellular and molecular level.
Additionally, those with chronic seizures experience cognitive, emotional and social impairments
(Briellmann et al., 2002; Ozkara et al., 2004; Thompson & Duncan, 2005; Locke et al., 2010).
Animals (Mortazavi et al., 2005; Gröticke et al., 2007) with chronic epilepsy also exhibit
behaviors associated with anxiety and depression, deficits in learning and memory, and motor
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impairments. These functional impairments are hypothesized to be due to neuronal damage,
circuit imbalance, hypoxic conditions and altered metabolism. Anatomical and physiological
abnormalities have been reported in the hippocampus after severe seizures such as status
epilepticus in animal models (Borges et al, 2003), and morphological changes have also been
reported in cortical astrocytes (Ding et al, 2007).
Status Epilepticus
Regardless of the specific classification or etiology, episodes of status epilepticus can
occur. Status Epilepticus (SE) is defined as a continuous seizure lasting more than 30 minutes or
two or more seizures without full recovery of consciousness between them (Cherian & Thomas,
2009). However, the defined time frame is dependent upon the method of investigation or the
treatment type and ranges from 5 minutes to 90 minutes. In humans, it has been found that if SE
lasts for five minutes, it will likely continue for at least twenty minutes but may spontaneously
remit (Bassin et al., 2002). It is important to note that permanent neurological damage or
pathophysiology can result from prolonged SE (Cherian & Thomas, 2009). Therefore it is
important that treatment stop the seizure. Some evidence also suggests that seizures may
become refractory and difficult to control if treatment is delayed. Animal models of epilepsy
have reported significant structural brain damage after 30 minutes of SE (Scott et al., 1998).
Results found in animal models don't always translate to humans and prove to be more difficult
to explain or demonstrate in patients (Duncan, 2006). Thus, the extent of neuronal injury in
humans due to seizure activity is currently unclear.
Common causes of SE include, but are not limited to, brain injury, cerebrovascular
disease, hypoxia/anoxia, tumor, infectious disease, drug and alcohol withdrawal, systemic and
metabolic illnesses, and noncompliance with antiepileptic drugs in patients with epilepsy (Bassin
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et al., 2002). Based on a prospective population-based study conducted at the Medical College
of Virginia, it is estimated that 100,000 cases of SE occur in the United States per year
(DeLorenzo et al., 1996). Recent reports of incidence approximate 50,000-150,000 cases present
with mortality rates estimated from 10-40% (Coeytauz et al., 2000; DeLorenzo et al., 1996). The
prevalence of epilepsy is high globally and incidence rates are growing due to the development
of epilepsy following head trauma and co-morbid diseases. Once an individual is recognized as
having seizure activity, the first line of treatment to prevent future seizures is anti-epileptic drug
(AED) treatment.
Epilepsy Treatments
Current treatment options are dominated by AEDs such as Valproate, Tegretol, and
Gabapentin. Although these drugs assist in reducing the seizures for most patients, about 30-40%
of patients are either unresponsive or poorly responsive to AED therapy. Additionally, these
pharmacological treatments do not usually address the origin or etiological mechanism of the
seizures. However, they may reveal important information regarding the regions, channels, and
cellular connections that contribute to seizure generation and activity. The pathways these drugs
utilize in the system are a good place to begin animal model investigations and are used in
experimental designs to examine questions regarding the changes that occur in chronic epilepsy
patients.
Many current pharmacological treatments for epilepsy act on widely expressed ion
channels that directly control neuron excitability (Rogawski & Loscher, 2004). For instance
Phenytoin, a drug that blocks certain sodium channels, reduces the rate of action potentials and
therefore inhibits high-frequency firing of neurons. Another pharmacological option is
phenobarbital, a GABA receptor agonist, which increases the efficacy at inhibitory synapses and
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therefore attenuates excitability.
There are non-pharmacological options for intractable epileptics that include surgical
resectioning or electrical stimulation devices such as Vagus Nerve Stimulators as well as noninvasive interventions such as the ketogenic diet and meditation. Only a small proportion of
epilepsy patients are eligible for the invasive treatment options such as surgery; whereas the less
invasive alternative methods are considered to be mostly complementary to the AED’s available
and are used less often as monotherapy for those with chronic seizures.
Because current treatment options for epilepsy do not offer successful control of seizures
for a large portion of epilepsy patients, new treatment options are needed. Experimental models
of epilepsy have been used in the search for novel therapeutic targets. Current AEDs and other
treatments are still focused on the immediate needs of the epileptic population and do not treat
the etiological source of the problem, nor do they address preventive measures to avoid
epileptogenesis or to protect against damage to brain structures in chronic epilepsy.
Experimental Models of Epilepsy
The use of animal models to further understand the changes in brain physiology and
circuitry that occur during seizures has provided a great deal of information that could not be
experimentally investigated using human subjects. Animal models have allowed researchers to
examine similarities in the patterns of anatomical and behavioral changes seen between rat
models and human patients with epilepsy in an effort to translate findings from basic research to
the clinic. Researchers using animal models have reported permanent changes in brain circuitry
after seizures (Mello et al., 1993), including cellular hyperexcitability and mossy fiber sprouting
(for review see Dudak & Sutula, 2007). Another critical consequence of chronic uncontrollable
seizures is neuronal loss. Humans with TLE show neuronal loss, sclerosis and atrophy, especially
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in the hippocampus (Briellman et al., 2002).
Animal models also report cell loss in various brain regions, especially in the limbic
system (Borges et al., 2003; Mello et al., 1993). Functional changes have also been reported in
animal models, including changes in cognition and emotion after seizures (Borges et al., 2003).
Different animal models of epilepsy exist, with two categories of models commonly
utilized to emulate TLE. One of these categories involves the administration of chemical
convulsants such as pilocarpine or kainic acid to induce an acute, severe excitotoxic episode
characterized by status epilepticus (SE). In this model, the acute phase is approximated to be 24
hrs and is followed by a latent phase lasting from 4 to 44 days and is characterized by the return
to normal electroencephalogram (EEG) and no seizure-related behavior. Following this latent
period is a chronic period of recurrent spontaneous seizures (Cavalheiro, 1995). The second
approach is known as “kindling” in which frequent but small insults via chemical or electrical
stimulation result in repeated seizures (Golarai et al., 1992). In this approach the animal develops
chronic epilepsy without experiencing an acute episode of SE. Both models result in
neuropathological and neurophysiological abnormalities that resemble those observed in human
patients with epilepsy. However, these abnormalities are less extensive when using the kindling
model. Abnormalities include neuronal loss, mossy fiber sprouting and synaptic reorganization
in the hippocampus that favors hyper-excitability (Dudek et al., 2007). All of these abnormalities
are thought to underlie the mechanisms of epileptogenesis (Wuarin & Dudek, 2001).
In the pilocarpine model of TLE, pilocarpine acts on muscarinic receptors (Hedlund et.
al., 1981) and its convulsant actions are often evoked in the presence of a peripherally acting
muscarinic antagonist such as, methyl-scopolamine (Cavalheiro et. al., 2006) or atropine to limit
peripheral cholinergic effects. This induction of SE by pilocarpine in rats lead to
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neuropathological changes such as hippocampal sclerosis and mossy fiber sprouting that
resemble human TLE. Therefore, among basic scientists, this model is representative of temporal
lobe epilepsy precipitated by convulsive status epilepticus that has been well-characterized
(Cavalheiro et al., 1991; Mello et al., 1993). Experimental models of seizures and epilepsy are
priceless tools in understanding the basic mechanisms underlying epileptogenesis.
CNS Reorganization
To begin to understand the basic mechanisms underlying seizure genesis and its resultant
outcomes, it is important to distinguish between ictogenesis and epileptogenesis. Ictogenesis, the
induction of the seizure, is due to excessive discharges from groups of neurons, initiated by
depolarized voltage-dependent sodium channels and activation of ionic glutamate receptors
(Sasa, 2006). Accordingly, the outcome or result of prolonged anatomical and biochemical
alterations and “aberrant” reorganizations of neuronal networks that stem from repeated episodes
of ictogenesis are known as epileptogenesis. It is well-known that epilepsy involves chronic
excitoxicity and results in aberrant sprouting or the formation of more excitable neuronal
pathways (Yang et al., 2003; Nobels, 2012)) suggesting refractory seizures may be due to
reorganization that favors hyper-excitability following chronic injury or insult in the CNS.
Reports have been controversial and the jury is still out as to whether these new synapses that
form following SE are contributing to the epileptogenic pathway. Data from animal models
suggest that these new synapses do indeed result in pathways that favor excitability (Buckmaster
et al., 1997;Ben-Ari et al., 2006). Reports by Sutula and colleagues show that aberrant sprouting
and new synapses form aberrant glutamatergic synapses (1988) and that this can be observed in
both human (Gabriel et al., 2004; Sutula et al., 1989) and in animal models (Buckmaster et al.,
1997).
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In human patients with epileptogenesis it is difficult to know what came first, the seizure
or the brain pathology. However, there are some neuroanatomical and neurophysiological
similarities found among patients with chronic SE such as hippocampal sclerosis, reactive gliosis
and astrocytic dysfunction, microvascular proliferation and synaptic organization (Matthern et
al., 1997; Blumcke et al., 2002) as well as social, cognitive and emotional dysregulation or
behavioral impairments (Briellmann et al., 2002; Yang et al., 2010). Pathology studies of human
epilepsy tissue show reorganization that favors hyperexcitability, particularly in the dentate gyrus
granule cells. These changes include a loss of subgranular hilar interneurons, mossy cells and
granule cells, and the development of mossy fiber sprouting, glial activation and neuronal loss.
Evidence is accumulating supporting changes following chronic seizures or SE in many cell
types. Although most reports in early work focused on neuronal loss and dysfunction, over the
past few decades evidence from studies of other cell types is building and research is ongoing to
reveal how they may be contributing not only to these neuronal changes (Seifert et al., 2006;
Schroder et al., 2000; Wetherington et al., 2008) but also to the generation of the seizure itself
(David, 2009). One of the cell types that has been receiving the most attention in this regard is
the astrocyte.
Astrocytes in CNS
Astrocytes are involved with information processing, synapse formation and clearance of
extracellular neurotransmitters. Astrocytes serve many roles that include the uptake of
potassium, water, glucose, and neurotransmitters (glutamate, GABA, glycine). Additionally,
astrocytes release many substances such as nitric oxide (NO) and arachidonic acid (AA)
associated with blood vessel regulation, lactate for energy, glutamate and precursors for
glutamine neurotransmitters that help regulate neuronal excitability, purines, neurosteroids and
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growth factors such as BDNF, VEGF, and TNF-α. Additionally, astrocytes secrete substances
such as thrombospondin that are associated with synapse formation (Christopherson et al., 2005;
Eroglu et al., 2009).
Astrocytes have direct contact with blood vessels, neuronal synapses, and nodes of
Ranvier. They also have gap junctions with adjacent astrocytes and the ability to reach and
service many neurons simultaneously. Evidence also exists that they have direct connection with
neural progenitor cells (Vezzani et al., 2005). Astrocytes can stimulate neurite outgrowth and
contribute to synaptic formation (Ullian et al., 2001). Therefore, astrocytes are not only
important in ionic balance and metabolic action, but also in the control of balancing excitation
and inhibition, modulating information processing, and the formation of synapses.
Because of their broad interactions, astrocytes could be more intricately involved in
functional and physiological abnormalities than previously suspected. The heterogeneity of
astrocytes and the high level of specificity in the connectivity of astrocytic networks make this
role even more likely (Sul et al., 2004). In an interview with Maiken Nedergaard, attention is
drawn to the much slower signaling of astrocytes when compared to neurons. She proposes this
may enable astrocytes to “process the information in a more sophisticated manner and retrieve
memories” (Nedergaard & Oberheim, 2009). Based on their range of action, alterations of
astrocyte morphology and function could lead to the memory impairment so typically observed
in patients with epilepsy. However, in order for one to speculate about the astrocyte changes that
may underlie dysfunction; one must first discuss the way these cells function under normal
conditions.
In general, astrocytes are star-like cells with radially arranged processes. The cytoplasm
of astrocytes contains intermediate filaments composed of a distinguishing protein glial fibrillary
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acidic protein (GFAP) that is often used in studies to distinguish astroglia from neurons. The
processes of astrocytes form an infrastructure that anchors all other CNS cell types. The role of
astrocytes as supportive to neurons was proposed by early neuroanatomists. However, the
discovery of new techniques for visualizing glial cells has allowed us to better study how
astrocytes function within the CNS.
Astrocytes outnumber neurons in human brains over fivefold (Sofroniew & Vinters,
2010) and form half of the human brain’s total volume. However, in rodents astrocytes
outnumber neurons to a lesser extent and this ratio shift should be considered in animal models
of neurological disease. Astrocytes also have interactions with endothelial cells and serve to
maintain ionic balance (Sofroniew & Vinters, 2010; Abott et al., 2002) as well as support and
play a role in the repair of the nervous tissue they are responsible for (Pekny et al., 2005;
Sofroniew et al., 2005). Astrocytes have many ionic pumps including Na+K+, Na+Cl- and
K+Cl- transport systems (Parent, A.1996) that help mediate their many functions within the
CNS. Astrocytes undergo both cellular and molecular changes in epilepsy that include alterations
in glutamate transporters, receptors, Kir channels and water channels.
Sofroniew and colleagues (2005) report that the loss of CNS function after injury or
insult, is ultimately due to neuronal loss or dysfunction. However, they propose that glial cells
are primary responders to CNS insults and are therefore in a position to be key determinants of
clinical outcome (Sofroniew, 2005). Reactive astrocytes are essential for both spatial and
temporal regulation of inflammation after CNS injury (Bush et al., 1999; Hermann et al., 2007).
Furthermore, Sofroniew and Vinters (2010) propose it is now clear that reactive gliosis occurs on
a continuum of changes that are context-dependent and regulated by specific signaling events.
One role of astrocytes is as an important component of the “neurovascular units.”
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Astrocytes, neurons, and microvessels form “neurovascular units” that together allow for the
modulation and regulation of blood flow and nutrients to support normal communication in the
CNS (Takano et al., 2006; Simard et al., 2004). Astrocytic end feet form tight junctions around
blood vessels and play a contributory role in the make-up of the BBB that serves many functions
ranging from supply of nutrients to mediating the efflux of many waste products. Astrocyte
processes also extend to the surface of the CNS to form the glial membrane beneath the Pia
Mater. Astrocytes form the line that separates the brain from the mesenchymal structures that
include capillaries, meninges and vascular adventitia.
Functionally, astrocytes are broadly involved in the regulation of brain metabolism and
function. Astrocytes have glycogen and activate glycogenolysis when neurons depolarize,
suggesting a role for astrocytes to provide neurons with energy. Additionally, astrocytes release
nitric oxide (NO) and arachidonic acid (AA) derivatives such as prostaglandins and leukotrienes
and other vasorelaxing factors indicating they may play a role in vasodilation and constriction,
respectively.
Astrocytes also function to maintain adequate extracellular potassium and glutamate to
control the microenvironment (Parpura & Haydon, 2009). The astrocyte membrane is more
permeable to potassium than the neuronal membrane and astrocytes prevent increased
extracellular potassium and spreading depression via “spatial buffering” and the astrocyte
syncytium. Astrocytes also have a higher capacity for glutamate uptake when compared to
neurons.
Astrocytes can secrete extracellular matrix molecules and growth factors, which
influence the survival of neurons and allow for both axonal and dendritic sprouting (Barres &
Barde, 2000). Additionally, these cells promote synaptic formation, and maintain synaptic
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function, which may actively modulate synaptic transmission via the glutamate-glutamine cycle
(Pfrieger & Barres, 1996). Astrocytes may communicate with neurons via the release of
gliotransmitters using a calcium-dependent mechanism. One important aspect to consider, in
light of more recent work, is the growing information regarding astrocyte heterogeneity even
within the same brain region.
Types of Astrocytes
In the CNS there are three types of astroglia: 1) fibrous, found mostly in white matter and
possessing few organelles, 2) protoplasmic, possessing many organelles and generally located in
the gray matter, and 3) radial, located at the interface between gray matter and the pia mater. It is
important to consider these subtypes when speculating about the function of astrocytes in the
CNS. Differing astroglia subtypes are associated with differing responses and therefore may play
different roles within the CNS.
Astrocytes display a high degree of phenotypic plasticity since they respond to various
stimuli via change of form, function, and rate of multiplication (Parent, A., 1996). According to
work by Barres and colleagues over the past decade or so, the largely specified gene expression
profiles of astrocytes (Cahoy et al., 2008; Doyle et al., 2008) speaks to the functional diversity of
these cells and hence their interactions with other cell types and ultimately in their contribution
in the metabolism of neurotransmitters that are so crucial in epilepsy (Zhang & Barres, 2010).
Future studies are ongoing in an attempt to provide information regarding the distinct role or
various roles each astrocyte subtype may play as well as any findings that may reveal
information regarding astrocyte differentiation or de-differentiation that may occur in response to
specific types of insults or in particularly crucial regions of the CNS. It has been demonstrated
that the heterogeneity of astroglia must be considered due to recent findings that cells with
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astroglial properties can express glutamate transporters but ionotrophic receptors (classic
astroglia) while other subsets express ionotrophic receptors but not glutamate transporters and
are known as NG2 glia or GluR cells (Matthias et al., 2003; Nishiyama et al., 2005). Studies
show that NG2 cells lack gap junction coupling but receive direct synaptic input from
GABAergic and glutamatergic neurons (Lin & Bergles, 2004; Wallraff et al., 2004; Jabs et al.,
2005). Zhou and colleagues suggest that NG2 cells are another subtype of astrocytes and should
no longer be classified under “complex” astroglia (2006).
Astrocytes & seizure
Astrocytes in the “normal” brain have a domain organization that is spatially nonoverlapping. However, with chronic seizures, the hippocampal astrocytic domain organization is
altered such that astrocytic processes are overlapping at a rate of approximately an 8-15 fold
increase in a rodent model. This loss of domain organization is prevented or reduced in seizure
patients receiving typical pharmacological treatments (Oberheim et al., 2008). Morphological
changes in astrocytes were accompanied by neuronal changes such as hypertrophy of apical
dendrites and increased spine density, suggesting that these changes are associated with the
development of recurrent excitotoxicity. Findings suggest that reactive astrocytes exert both pro
and anti-inflammatory functions dependent upon the location and timeframe investigated in
response to injury and during repair (Bush et al., 1999; Faulkner & Hermann, 2004). Bush and
colleagues report that the ablation of reactive astrocytes following experimental brain injury
results in massive tissue edema in the local tissue, suggesting that reactive astrocytes may help
regulate tissue fluid levels and toxic edema will result if astrocytes lose the ability to perform this
important function. Furthermore, NMDAr antagonists attenuate neuronal death, suggesting that
astrocyte loss results in accumulation of extracellular glutamate and leads to excitotoxicity of
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both neurons and oligodendrocytes (Bush et al., 1999). This ides is consistent with the findings
of Rothstein’s group, who report that deletion of genes encoding astrocyte specific glutamate
transporters exacerbates glutamate receptor-mediated excitotoxicity (1996). Astrocytes also have
the ability to release glutamate, which could induce an imbalance of excitation and inhibition in
the local circuit, and could influence epileptiform events such as the paroxysmal depolarizing
shift (PDS) (Nedergaard et al, 2005).
Astrocytes may wield non-stereotyped bimodal synaptic control via release of
gliotransmitters such as purine, which imparts inhibitory control, and glutamate, which imparts
stimulatory control (Volterra & Meldolesi, 2005). Some work is shedding light on subtypes of
astrocytes and proposes those with presence of AMPA Glu receptors do not have glutamate
transporters; whereas another subtype contains glutamate transporters but not glutamate
receptors and have extensive gap junction coupling (Mathias, 2003). This work suggests the
presence of GluR cells that appear identical to NG2 cells but have increased Ca++ oscillations
and can be depolarized to release action potential like responses. GluT cells are reported as
almost completely lost in sclerotic tissue, suggesting that only GluR cells remain, potentially
leading to the increased glutamate and extracellular potassium that result in excitotoxicity. Given
that both of these gliotransmitters have various receptor targets on both excitatory and inhibitory
neurons, and that astrocytes also release other gliotransmitters, the complexity may be difficult to
decipher without further understanding the distinct roles these various subtypes of astrocytes
may play and how they respond to typical conditions of excitotoxicity.
The loss of astrocytes following CNS injury early on may lead to secondary degeneration
of other cell types (Liu et al., 1999; Zhao et al., 2003). Reactive astrocytes express fibronectin
and can support the regrowth of certain types of CNS axons along their cell surface (Gage et al.,,
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1988; Tom et al., 2004), so their loss could impede these processes.
Astrocytes show many changes in human epilepsy and reports include the expression of
specific glutamate receptors, redistribution of AQP4, increase sodium and calcium channels as
well as decrease in Kir 4 1 channels (Nobels et al., 2012). This group also reports reduction in
GS and lactate dehydrogenase and some increase in immune molecules. It is necessary to
recognize that astrocytes with these changes can be categorized into subtypes that should be
considered in future studies. Findings suggest sclerotic tissue cells may have cells capable of
Ca++-dependent excitotoxic glutamate release and swelling resultant of APQ4 changes may also
facilitate astrocytic release of glutamate and will lead to alteration of Kir channels. One
consistent finding of astrocytic alteration that is reported is reactive gliosis and has become a
marker for astrocytes under pathological conditions (Sofroniew et al., 2010).
Reactive Astrocytes
Astrocytes respond or become reactive in response to many forms of CNS insults through
a process known as reactive gliosis. The extent of reactive gliosis and its duration is dependent
upon the type and severity of the insult (Pekny & Pekna, 2004). Reactive gliosis marks
pathological tissue according to the literature (Sofroniew, 2009) and signs of CNS regeneration
become more prominent in experiments that report the effects of attenuating reactive gliosis
long-term (Pekny et al., 2004; 2005) More recently, Pekny and colleagues have reported that
reactive gliosis is accompanied by the altered expression of many genes. In this same article they
propose that reactive gliosis immediately following an insult may serve a neuroprotective role,
but at later stages reactive gliosis may facilitate the formation of a glial scar that inhibits synaptic
formation and compromises neural graft survival and integration.
Reactive astrocytes show changes in regulatory functions in various channels that may
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exacerbate dysregulation of the microenvironment if persistent for long periods. However,
reports are inconsistent and do not provide a clear picture of this phenomenon. One view is that
astrocytic gliosis leads to glial scarring and therefore prevents axonal regeneration in the CNS. In
contrast, many reports have established that one benefit of glial scarring is the demarcation of
damaged tissue and the decreased spread of the inflammation response to adjacent tissues
(Sofroniew, 2005). IL-1β, a potent pro-inflammatory cytokine, is upregulated during
epileptogenesis in astrocytes but not microglia, suggesting a prominent role of astrocytes in
sustaining chronic inflammation before the onset of spontaneous seizures (Ravizza, 2008).
However, reactive gliosis at later time points, following injury or insult, may be more
detrimental than beneficial. The findings of Lider and colleagues (1995) suggest that reactive
gliosis leading to inhibition of axon regeneration may be a byproduct of the redundancy of
migratory guidance cues among and between the cell types speaking to the importance of
attenuating reactive gliosis beyond the necessity to prevent inflammatory spreading to adjacent
tissue following insult or injury. Liberto and colleagues (2004) report the contrasting view that
cytokines activate astrocytes and that this activation can promote the recovery of the CNS
function.
Astrocytes have been shown to secrete extracellular matrix molecules and growth factors
that influence the survival of neurons (Barres & Barde, 2000), can promote synaptic formation
and maintain synaptic function via glutamate uptake (Pfrieger & Barres, 1996). In particular,
animal models of neurological disease demonstrate a change in levels of astrocyte-secreted
thrombospondin that appears to be involved with synapse formation. Thrombospondin proteins
such as thrombospondin-1 (TSP1) and TSP2 are produced by astrocytes and contribute to the
development of synapse formation and neural plasticity. Garcia and colleagues (2010) reported
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that knockout mice or depletion of TSP1 resulted in changes in spine morphology, while
restoration of TSP1 prevented these alterations. Recently it was demonstrated that TSP1 is
necessary for synaptic and motor recovery after stroke (Liauw, 2008) suggesting that this plays a
role in neural plasticity.
Another important function of astroglial activation is growth factor release. One such
growth factor is vascular endothelial growth factor (VEGF), which has been implicated in
neuroprotection. Astrocytes have themselves been shown to be VEGF responsive (Croll et al.,
2004; Ackerman et al., 2003; Mani et al., 2005). Since VEGF has been shown to protect neurons
from excitotoxicity (Nicoletti et al., 2008; Matsuzaki et al., 2001), there is reason to speculate
that it plays a role in the protection of astrocyte organization as well. Given that glial cells have
been reported to express VEGF receptors both constitutively (Krum & Rosenstein, 2004) and
after seizures (Nicoletti et al., 2008), it is possible for VEGF to impact their function or
morphology.
Astrocyte Signaling in Epilepsy
More and more evidence is developing that points to the contribution of glial cells to
epilepsy and other CNS disorders (Steinhauser & Seifert, 2012; Aronica et al., 2012; Oberheim
et al., 2008; Tian et al., 2005; Kang et al., 2005). Glial cells in epilepsy show redistribution of
glutamate receptors, AQP4, increase in Na+ and Ca++ channels and decreased Kir channel
activation. Enzyme changes such as reductions in glutamine synthetase (GS) and lactate
dehydrogensase also occur. In addition, immune molecules are increased in astrocytes studies in
epileptic brains (Nobels, 2012).
Early work established astrocytes to be crucial in maintaining the balance of the
extracellular environment; specifically in limiting K+ and glutamate (Kuffler & Potter, 1964;
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Newman, 1984). Astrocytic “spatial buffering” and the knowledge that extracellular potassium
influences excitability, has driven a surge in research that reveals interesting information and
proposes an astrocytic basis of epilepsy. Wallraff and colleagues (2006) report that astrocytic,
not neuronal, inward-rectifying K+ channels are indicated in downregulation of Kir channels and
reduced spatial buffering. Yaron David and colleagues (2009) used a NEURON model to
assimilate the reduced uptake of potassium and glutamate on EPSPs and results showed an
accumulation of glutamate to be associated with frequency-dependent decreased facilitation of
EPSPs. In addition, potassium accumulation leads to frequency-dependent NMDA-dependent
synaptic facilitation, a phenomenon that electrophysiological recordings have confirmed can lead
to seizure-like activity.
It has been demonstrated that changes in expression, localization and function of the
Kir4.1 inward-rectifying potassium channel are reported in astrocytes in neurological disorders,
particularly in TLE (Olsen & Sontheimer, 2008). Additionally, attention has been focusing on
the role of Kir channels in cell division and Olsen’s group proposes that loss of Kir4.1 may
underlie the re-entry of glial cells into the cell cycle supporting gliosis (2008). Gliosis is
observed after most traumatic insults to the brain, including after status epilepticus. Blood-brain
barrier is also perturbed after status, which can lead to the leak of blood proteins into the brain.
Interestingly, albumin uptake into astrocytes is mediated by TGF-ß, which produces the
downregulation of Kir4.1 in astrocytes (Ivens et al., 2007). Kir4.1 expression is also influenced
by extracellular changes in other inflammatory cytokines such as IL-1ß (Zhang et al., 2011),
which are also upregulated after status. As further evidence of a possible role of astrocyte
signaling in epilepsy, deletion of the Kir4.1 gene in mice leads to inhibition of K+ and glutamate
uptake, hyperexcitability and seizures (Djukic et al., 2007). Mutations in the human Kir4.1 gene
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are also associated with epilepsy, suggesting a role for astrocytic potassium channels in human
epilepsy (Olsen & Sontheimer, 2008; Chevor et al., 2010; Zhang et al., 2011).
Astrocytes have been experimentally shown to contribute to epileptiform discharges in
the hippocampus (Kang et al., 1998; Tian et al., 2005). With chronic seizures, the hippocampal
astrocytic domain organization is altered such that astrocytic processes are overlapping at a rate
of approximately an 8-15 fold increase in a rodent model. This loss of domain organization is
prevented or reduced in seizure patients receiving typical pharmacological treatments (Oberheim
et al., 2008). Morphological changes in astrocytes were accompanied by neuronal changes such
as hypertrophy of apical dendrites and increased spine density, suggesting these changes could
form the foundation for recurrent excitotoxicity. In addition, it has been demonstrated that
increased astrocytic Ca++ signals play a role in neuronal excitotoxicity after status epilepticus
and that these signals were capable of inducing the release of glutamate which may contribute to
delayed neuronal death and later cognitive decline (Ding et al., 2007). Others have made similar
conclusions from their results that delayed neuronal death led to cognitive decline and later
epilepsy (Lemos & Cavalheiro, 1995).
Finally, astrocytes are responsible for glutamate-glutamine cycling and are key players in
maintaining a balance between excitation and inhibition. Imbalance in these processes is a
primary problem in seizures and likely contributes to epileptogenesis. Astrocytes use their
glutamate transporters, Glt-1, to internalize excess glutamate in the synapse, and then use the
enzymes glutamine synthetase and glutaminase to convert glutamate to glutamine. Astroglia are
responsible for 90% of glutamate clearance and regulation of extracellular glutamate levels
(Behrens et al., 2002; Bacci et al., 2002). Glutamine synthetase (GS) and glutaminase are
downregulated in epileptogenesis (Derouiche & Frotscher, 1991), providing further evidence for
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dysregulated astrocyte glutamate processing in epilepsy.
Astrocytes and Inflammation after Seizures
Astrocyte activation, like microglia activation, is a common component of brain
inflammatory responses, including those inflammatory responses observed after seizures. When
activated, glia can release pro-inflammatory cytokines. Elevations in these cytokines have been
reported in human patients and in experimental models of epilepsy (Vezzani et al., 2008;
Jankowsky & Patterson, 2001). Indeed, genetic susceptibility to inflammation appears to
positively correlate with risk for epilepsy, perhaps particularly in childhood epilepsies (Choi &
Koh, 2008). A rapid onset of inflammatory responses in glia is triggered by seizures (DeSimoni,
2000). It is well documented that chronic seizure activity results in cellular and molecular
changes to both neurons and glial cells. More recent reports are adding to the role of brain
inflammation in epileptogenesis (Kleen & Holmes, 2008). Immune-mediated damage to the CNS
is reported to contribute to epileptogenesis both directly through inflammation and indirectly by
causing BBB leakage (Choi et al., 2008; Croll et al., 2004). One study by Seiffert and colleagues
showed problems with opening of the blood brain barrier (BBB) after a latency of 4 days and
lasting up to 49 days and suggests this opening in the BBB may be epileptogenic and very
important in the development of seizure disorders. Although the mechanisms of BBB opening
during inflammation are unproven, multiple cell types in the brain have the ability to upregulate
and release VEGF, a potent vascular permeability factor (Senger et al., 1986). Upregulation of
VEGF by both neurons and astrocytes is marked after status epilepticus (Nicoletti et al., 2008),
and could represent one mechanism by which cells in the brain drive inflammatory processes
after seizures.
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VEGF
Vascular endothelial growth factor (VEGF) is a protein mitogen originally discovered for
its potent effects on vasculature (Senger, 1986). In spite of its vascular permeabilizing effects,
VEGF has been more recently investigated for its neurotrophic effects (for review see Carmeliet
& Storkebaum, 2002). Studies have shown that VEGF protects neurons in culture from a variety
of insults, including hypoxia, ischemia, and excitotoxicity (Jin et al., 2000, 2001; Matsuzaki et
al., 2001) and has been shown to protect against ischemic neuronal damage in vivo (Wang et al.,
2005; Bellomo et al., 2003; Sun et al., 2003; Hayashi et al., 1998). VEGF may play a role in
protecting neurons against neurodegenerative processes as is demonstrated in amyotrophic lateral
sclerosis (Storkebaum & Carmeliet, 2004; Zheng et al., 2004), Parkinson’s disease (Falk et al.,
2010), and epilepsy (Nicoletti et al., 2008).
The VEGF Family
In order to elucidate VEGF’s role in epilepsy, it is important to understand how VEGF is
produced endogenously. The human VEGF gene is located on chromosome 6p21.3 and is
composed of 8 exons separated by 7 introns with a coding region of approximately 14kb
(Vincenti et al., 1996). The promoter region is located near a cluster of potential binding sites
for Sp1, AP-1, and AP-2 transcriptional factors. These transcription factors regulate gene
expression and are involved in a number of cellular processes such as apoptosis, differentiation
and proliferation. Through alternate exon splicing, the VEGF gene codes for several isoforms of
VEGF, such as 121, 145, 165, 183, 189, and 206, each composed of a specific number of amino
acids (Tischer et al., 1991). Each VEGF isoform differs in its expression pattern and biological
properties. The murine VEGF gene is similar to the human VEGF gene with 8 exons divided by
7 introns encompassing 14kb, however, this gene only codes for 3 isoforms, 120, 164, and 188,
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which are shorter than human VEGF by one amino acid (for review, see Ferrara & Davis-Smyth,
1997). Because our experiments were conducted in rat, it is important to understand the
biophysical characteristics of human and murine isoforms.
VEGF121, VEGF165, and VEGF189 are the most commonly expressed forms of VEGF and
have been found in a wide range of tissues while VEGF145 and VEGF206 are relatively rare and
limited to cells of placental origin (Robinson & Stringer, 2001). VEGF183 has recently been
identified and is a less frequent splice variant. All isoforms bind heparin except VEGF121, which
is released as a freely soluble protein. VEGF189 and VEGF206 bind to heparin with high affinity
and are almost completely sequestered in the extracellular matrix after secretion (Zachary &
Gliki, 2001). VEGF165, which is the major isoform found in most mammalian tissue, is secreted
as a 46,000 dalton heparin-binding homodimeric glycoprotein. Its intermediate affinity for
heparin results in a significant portion remaining bound to the extracellular matrix and cell
surface (Robinson & Stringer, 2001). It has been demonstrated that VEGF protein becomes
available to endothelial cells as freely diffusible proteins, as is the case with VEGF121 and
VEGF165, or it must be cleaved by plasmin at the COOH terminus, as is the case with the longer
forms bound in the extracellular matrix (Keyt et al., 1996). While there is an inverse relationship
between heparin affinity and diffusibility, there is a direct relation between the affinity of each
isoform for heparin-binding and its mitogenic activity. Typically, those with a higher affinity for
heparin exhibit greater mitogenic activity for vascular endothelial cells although this is not
necessarily the case for all isoforms particularly VEGF165 and VEGF189 (Ferrara, 2001).
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Table 1. Major VEGF isoforms and their properties (adapted from Ferrara, 2001). It appears
that VEGF165 has the greatest bioavailability combined with biological potency.
VEGF Family and Receptors
The VEGF family of growth factors bind with high affinity to three receptor tyrosine
kinases (RTKs),: VEGFR1 also known as Flt1, VEGFR2 also known as Flk1 or KDR, and
VEGFR3 also known as Flt4,. In addition, they bind to the non-catalytic receptor family, the
neuropilins (Soker et al., 1998; Neufeld et al., 1999; Glutzman-Poltorak et al., 2001). The
VEGFR family of tyrosine kinase receptors triggers the activation of signaling pathways such as
the Erk/MAPk pathway or the Akt pathway (Gerber et al., 1998). VEGFR3 is not found in brain,
and is therefore unlikely to contribute to VEGF's CNS effects. When VEGF binds VEGFR1 and
VEGFR2 in the brain, these receptors dimerize. This causes the RTKs cytoplasmic tyrosine
kinase domain to autophosphorylate, triggering an intracellular signaling cascade that transduces
the original signal of VEGF binding into the cell. VEGFA, the most abundant VEGF family
member, binds to both VEGFR1 and VEGFR2. Reports demonstrate that both VEGFR1 and
VEGFR2 are expressed on neurons and glial cells (Krum et al., 2002), and that both RTKs are
densely localized to hippocampus. However, it is important to recognize that VEGFR1 has been
reported to gradually decrease during development whereas VEGFR2 increases gradually and is
observed at its highest numbers in the adult brain in the hippocampus (Yang et al., 2003). Falk
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and colleagues (2010) reported that mice with genetic deletion of VEGFR1 die from abnormal
vascular development, the pattern of which suggested that VEGFR1 may regulate VEGFR2
activation by serving as a decoy receptor.
Many studies implicate VEGFR2 as the more likely pathway to neuroprotection. For
instance, Cao and colleagues (2004) propose that VEGFR1 could be ruled out as responsible for
a reduction in excitability due to the observation that VEGFR1 produces a decreased potassium
current and a decrease in the delayed rectifier after exposure to VEGF and would therefore lead
to an increased rather than a decreased excitability (Cao et al., 2004). VEGFR1 is upregulated in
reactive astrocytes, and blockade of VEGFR1 reduces astroglial mitogenicity, scar formation,
and expression of growth factors (CGF & FGF). Blockade of VEGFR2 reduced vascular
proliferation around a brain wound site and increased endothelial degeneration without effects on
astrogliosis or growth factor expression (Harris A., 2002) suggesting that VEGF may induce
angiogenesis, astroglial proliferation and expression of growth factors via VEGFR1. This idea is
also supported by results of exogenous VEGF administrated in TBI (Thau-Zuchman et al., 2010).
Differential binging to VEGFR1 versus VEGFR2 is not responsible for all of the
variability in the effects of VEGF in the brain. VEGF's non-catalytic co-receptors, the
neuropilins, are highly localized to brain and have been shown to modulate the effects of VEGF
binding at its RTKs (Chedotal et al., 1998). The neuropilins include neuropilin 1 and neuropilin
2 (NRP1 &2). Neuropilin 1 (NRP1) is expressed by both endothelial cells and neurons and
serves as a receptor for both VEGF and Semaphorin 3A (Sema 3A), an inhibitory mediator of
axonal guidance. They neuropilins were first identified through their key role in mediating
axonal guidance via interactions with semaphorins in the developing nervous system (Yang et
al., 2004). Studies have demonstrated that Sema3A, Sema3B and Sema3F compete with VEGF
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for neuropilin binding (Miao et al., 1999) and that soluble NRP1 may act as a VEGF antagonist
(Gagnon et al., 2000). Downregulation of NRP1 by NRSF overexpression reduced Sema3A
activity (Kurschatt et al., 2006). One translation research study reported pilocarpine increases
NRSF but if block NRSF from binding attenuates epileptogenesis (McClelland et al., 2011).
Neuropilin 2 also binds semaphorins but Sema3E and Sema IV but not III. NPR2 is reported to
selectively mediate repulsive guidance events in discrete neuron populations during neural
development (Giger et al., 1998). Together this suggests that these co-receptors and their
affinities may reveal important information regarding structural basis of receptor function and
specificity (Giger et al., 1998). Soker and colleagues demonstrated that NRP1 enhanced the
binding of VEGF to VEGFR2 (2002). VEGFA binds both NRP1 and 2; whereas VEGFB and
PlGF only bind NRP1.

Figure 1. The VEGF family members, their receptors, the receptor tyrosine kinases VEGR-1,
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VEGFR-2, and VEGFR-3 and co-receptors Neuropilin-1 and Neuropilin-2 (adapted from Croll et
al., 2006).
VEGF Regulation
Several variables appear to play a role in the expression of the VEGF gene. Reports have
demonstrated that activity of the mTORC pathway leads to VEGF upregulation (Elving et al.,
2012). One key contributor to VEGF expression is hypoxia. Hypoxic conditions result in the
binding of hypoxia-inducible factors (HIFs) to the hypoxia response element (HRE) where the
promoter region of the VEGF gene is located (Carmeliet et al., 1998; Marti & Risau, 1998). The
ability of HIFs to upregulate VEGF appears adaptive under hypoxic conditions as VEGF serves
to increase vasculature in the hypoxic region that increases the amount of oxygen and nutrients
delivered to metabolically-compromised neurons. In the context of seizures, cells become more
metabolically active, and as their need for glucose and oxygen increases they may experience a
“relative” state of hypoxia. These hypoxic conditions may lead to VEGF upregulation in an
effort to preserve cells during seizures.
VEGF and Epilepsy
Both VEGFA and VEGFB have been shown to be upregulated in patients with intractable
epilepsy but VEGFA is upregulated in both neurons and astrocytes; whereas VEGFB is only
upregulated in neurons. Work from our own laboratory has demonstrated that VEGFA is also
upregulated in animal models of epilepsy (Nicoletti et al., 2008). Mice that overexpress
VEGFR2 upregulate VEGF in neurons and glia after seizure relative to wild type mice, and these
mice also show less seizure-induced neurodegeneration in vivo, accompanied by an increase in
seizure threshold and decrease the duration of focal after discharges suggesting an anti-ictal
effect (Litsa Nikitidou et al., 2012). Furthermore this group found no significant effects on blood
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vessels or glia suggesting increased VEGF signaling in VEGFR2 overexpressing mice may
directly affect seizure activity without altering angiogenesis.
We have previously reported that VEGF protein is not only strikingly increased in both
neurons and glial cells following pilocarpine-induced status epilepticus, but is also
neuroprotective against status epilepticus-induced neuronal loss in the hippocampus when
measured 24 hours following the seizure induction (Nicoletti et al., 2008). A recent review by
Ann Marie Vezzani (2005) proposed that not only does VEGF produce neurogenic effects that
affect neuronal function; but that the mechanism of this phenomenon may be due to VEGF’s
effects on neuronal progenitors.
In addition to effects on neurons, VEGF effects, at least in part, may have an astrocytic
basis as opposed to or in conjunction with a neuronal one. Interestingly, reports have been
published showing astroglia to both have VEGF receptors (Krum & Rosenstein, 2002) and be
VEGF responsive (Ackerman et al., 2003; Croll et al., 2004; Mani et al., 2010). Additionally,
Croll and colleagues reported the expression of VEGF shows a pattern of immunoreactivity that
envelops glial-like cells (Croll et al., 2004). McCloskey and colleagues (2005) found that VEGF
treatment reduced hyperexcitability without altering neuronal membrane properties suggesting
that non-neuronal mechanisms, such as those mediated by astrocytes, cannot be ruled out.
Specific Aims
The goal of this dissertation was to study astrocyte morphology and astrocyte glutamate
transporter expression following VEGF administration within the context of pilocarpine-induced
status epilepticus (SE), to determine VEGF's effects on astrocytes in this context. Our primary
objective was to better understand changes in astrocyte morphology that could reflect beneficial
changes in astrocyte function contributing to the protective effects of VEGF on hippocampal
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function after SE. We conducted this experimentation with the following specific aims:
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Specific Aim 1: To determine whether VEGF administration during status epilepticus
alters long-term astrocyte patterning or the inter-astrocyte distance in the rat
hippocampus.
To investigate inter-astrocyte distances, neighboring astrocytes were measured from soma center
to soma center in tissue stained with the astrocyte marker GFAP. Astrocytes from rats receiving
exogenous VEGF in the dorsal hippocampus were compared to those receiving inactivated
VEGF in both pilocarpine-treated and saline-treated animals.
Specific Aim 2: To determine whether administration of VEGF during status epilepticus
alters the long-term morphology of astrocytes in the dorsal hippocampus after status
epilepticus in rats using a branched structure analysis.
To investigate astrocytic morphological changes that occur following status epilepticus in
animals receiving VEGF protein versus those receiving inactivated VEGF control, hippocampal
astrocytes were traced and reconstructed using Neurolucida software (Microbrightfield, Inc.).
More specifically, any changes such as branch structure, branch order, diameter of processes,
length of processes, astrocyte surface volume, mean tortuosity, aspect ratio and roundness were
measured by performing Branched Structure Analysis using the Neuroexplorer software program
(MicroBrightfield, Inc.) Astrocytes from rats receiving exogenous VEGF into the dorsal
hippocampus were compared with those receiving inactivated VEGF in both pilocarpine-treated
(experimental condition) and saline-treated (control condition) rats.
Specific Aim 3: To determine whether administration of VEGF during status epilepticus
alters the long-term morphology of astrocytes in the dorsal hippocampus after status
epilepticus in rats using Sholl analysis.
To investigate astrocytic morphological changes that occur following status epilepticus in
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animals receiving VEGF protein versus those receiving inactivated VEGF control, hippocampal
astrocytes were traced and reconstructed using Neurolucida software (Microbrightfield, Inc.).
More specifically, any changes in the number of intersections and the length of the processes at a
distance of 5 mm increments moving away from the soma were measured using a Sholl Analysis
and the Neuroexplorer software program (MicroBrightfield, Inc.) Astrocytes from rats receiving
exogenous VEGF into the dorsal hippocampus were compared with those receiving inactivated
VEGF in both pilocarpine-treated (experimental condition) and saline-treated (control condition)
rats.
Specific Aim 4: To determine whether administration of VEGF during status epilepticus
alters long-term astrocyte glutamate transporter levels or patterns of expression in the rat
hippocampus with or without status epilepticus.
To investigate potential alterations in glutamate transporter expression in the
hippocampus of rats receiving VEGF or inactivated VEGF during and following status
epilepticus that could indicate altered capacity for glutamate uptake/reuptake, which could
impact hippocampal circuit excitability. Immunohistochemical staining for glutamate
transporters were conducted followed by quantitative analysis to investigate the relative density
and compartmentalization of glutamate transporters.
Specific Aim 5 –To determine whether any of the alterations observed in astrocytes treated
with VEGF during status epilepticus were predictive of hippocampal function as evaluated
by behavioral tests of hippocampally-mediated cognition.
To determine whether changes in astrocyte morphology was predictive of behavioral
function, animals were studied in three behavioral tests were conducted 2-4 weeks after SE. A
Morris Water Maze was used to measure hippocampally-mediated learning and memory, a
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light/dark exploration task as a measure of anxiety, and a grid locomotor task was used to
measure locomotor and exploratory drive. Behavioral data were then regressed against the
topological and metric measures from the branched structure analysis and Sholl analyses to
determine whether any of these astrocyte measures were significantly predictive of behavioral
function in the animals.
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Chapter 2: Methods & Results

Day -12

Day -5

Day 0

Day 14

Day 28-30

VEGF depleted

Start treatment with
VEGF or control via
osmotic minipump

Induce status
epilepticus
with pilocarpine

Behavioral testing
begins and continues for
approx.10 days

Sacrifice animals for
tissue collection

Figure 2. Timeline of of procedures from intial surgery to tissue collection.

EXPERIMENTAL PROCEDURES
Subjects
All subjects were adult male Sprague Dawley rats (Charles River, Laboratories,
Kingston, NY, USA) weighing 350-450 grams. Animals were housed 3 per cage within a
temperature controlled facility with food and water available ad libitum. All animals were
maintained on a 12 hr. light-dark cycle. All experiments were approved by the Queens College
Institutional Animal Care and Use Committee which operates under federal and state animal care
guidelines. All experiments conformed to international guidelines on the ethical use of animals
and every effort was made to minimize the number of animals used and to maximize their
comfort. Male Sprague Dawley rats were used because of the strong history of use of this model
in this strain and the desire to use an outbred strain.
Proteins
The VEGF administered for protein infusions was human recombinant VEGFA165
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(generous gift of Regeneron Pharmaceuticals, Tarrytown, NY, USA). VEGF was kept frozen (at
-80°C) until use and was then thawed and diluted in sterile phosphate-buffered solution (PBS)
(Sigma-Aldrich, St. Lois, MO, USA) to attain a dosage of 45 ng per day infused at a rate of 0.5
µl per hr. delivered via a two-week osmotic mini-pump (Alzet Model 2002; Durect Corporation
Cupertino, CA). This dose was selected based on previous dose curve studies within our lab that
showed 15ng per day or lower to have no effect and 60 ng per day or more to sometimes result in
overt angiogenesis in the brain when using human VEGFA 165 (Nicoletti et al., 2008).
Inactivated VEGF was used as the control protein (inactivated by repeated freeze-thaw cycles)
and PBS was mixed from powder form and sterilized in the autoclave before use. Protein
reagents were continuously infused into the dorsal hippocampi starting 5 days before pilocarpine
seizure induction and continuing for 2 weeks.
Cannula and pump implantation for protein infusions
Animals receiving protein infusions, whether active or inactive VEGF protein, were
anesthetized using 1mg/kg of sodium pentobarbital (Sigma-Aldrich) delivered via intraperitoneal injections. Cannula implantation surgeries were performed by first shaving the scalp
and neck area and applying alcohol to clean the incision site and then betadine iodine solution to
create a barrier against infection. Animals were placed into a stereotaxic apparatus and a
longitudinal incision was made along the scalp. Burr holes were drilled into the skull using a
Dremel drill and three anchor screws were inserted to provide stability to the skull cap. Two
sterile cannula, 4mm in length, each with an attached heat-sealed polyvinyl catheter tube
(Plastics One, Roanoke, VA, USA) containing sterile PBS were implanted bilaterally into the
dentate gyrus of the dorsal hippocampi at coordinates AP -3.8 and ML -/+2.7 measured from
bregma. This location was based on previous findings that VEGF diffuses over a 3mm diameter
(Croll et al., 2004b) allowing for diffusion of VEGF throughout most of the dorsal hippocampus.
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A dental acrylic mixture was then applied to secure the cannula to the anchor screws, forming a
stable skull cap. The surgical incision was then closed using nylon sutures, topical antibiotic
cream was applied, and animals were placed under a heat lamp to recover.
Animals were given one week for surgical recovery and then pump implantation
surgeries were performed. Animals were re-anesthetized in a chamber filled with an isofluraneoxygen mixture and placed into a nose cone delivering 2.5-3% isoflurane in 100% oxygen for the
duration of the pump implantation surgery. An incision was made at the nape of the neck, at
which time both catheter tubes were located. The heat-sealed tips were cut off the catheters and
Alzet osmotic minipumps (Durect Corporation, Palo Alto, CA, USA) filled with either active or
inactivated (freeze-thawed several times) rhVEGFA 165 (Regeneron Pharmaceuticals,
Tarrytown, NY) were glued onto the catheters with cyanoacrylate glue. VEGF was delivered at
45ng per day at 0.5 µl per hour for two weeks. The pump was inserted into a subcutaneous
pocket at the nape of the neck, the incision was closed using nylon sutures, topical antibiotic
cream was applied, and animals were placed under a heat lamp to recover.

Inactivated VEGF
treatment

VEGFA 165
treatment

Non-Seized

N=3

N=3

Pilocarpine-induced SE

N=5

N=5

Table 2. Shows the experimental design including the four group conditions and number of
animals in each condition. Each animal was then represented by multiple parameters quantified
in eight astrocytes from the CA1 region and 10 astrocytes from the dentate gyrus region relevant
to describing astrocyte morphology.
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Acute seizure induction
Exactly five days following pump implantations for protein infusions, animals were given
subcutaneous injections of atropine methyl bromide (1mg/kg) 30 minutes prior to intraperitoneal
injections of pilocarpine hydrochloride at 350 mg/kg (Sigma-Aldrich). The atropine was
administered before the pilocarpine to prevent any systemic cholinergic effects of the pilocarpine
such as excessive saliva production. Seizures were scored using a modified Racine scale (1972)
in which stages 1-4 were identical to the originally published Racine scale but stage 5 was
defined as transient whole body tonus, stage 6 was status epilepticus (SE), stage 7 was SE with
prolonged tonus, and stage 8 was seizure-related death (modified scale published in Rudge et al.,
1998).
Status epilepticus was truncated at one hour with 10mg/kg of diazepam (Henry Schein,
Melville, NY, USA) given intraperitoneally (i.p.). Animals that did not reach SE were given
10mg/kg of diazepam intraperitoneally one and a half hours after the pilocarpine hydrochloride
injection. Animals not reaching SE were excluded from all histological analyses. Control
(unseized) animals received both a pre-treatment subcutaneous injection of atropine and an i.p.
injection of diazepam one and half hours following the vehicle (PBS) injection given in place of
the pilocarpine hydrochloride.
Fixed Tissue Collection for Histology
Animals were deeply anesthetized 4 weeks after the seizure inductions and transcardially
exsanguinated with heparinized saline (.9%) followed by transcardial perfusion fixation using
4% paraformaldehyde in acetate and then borate solution, as previously described (Croll et al.,
1999). The brains were extracted and placed in a 30% sucrose borate buffer at 4ºC until
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sectioning
Sectioning
After 3-7 days in the buffered sucrose solution, brains were sectioned coronally at 50µm
using a sliding microtome (American Optical Company, Buffalo, New York). Sections were
placed in a 24-well plate and stored in an ethylene glycol-based cryoprotectant solution (Watson
et al., 1986) at -20 degrees Celsius until stained.
Immunohistochemistry
Glial fibrillary acid protein (GFAP): Sections were immunostained using a Vector stain Elite
ABC kit (Vector Laboratories, Burlingame, CA, USA) and rabbit anti-glial fibrillary acid protein
(GFAP rabbit polyclonal, 1:60,000, Dako, Carpinteria, CA, USA) commonly used to visualize
astrocytes (for review see Scharfman et al., 2000). To control for non-specific binding of
antibodies, sections of each animal were also stained with the same procedure with the exclusion
of the primary antibody. These sections were examined and showed no specific staining pattern.
GFAP immunostaining was conducted as follows: Tissue was rinsed several times for 15 minute
intervals in 50mM of KPBS (90% D2H2O, 8% dibasic potassium phosphate, 2% monobasic
potassium phosphate and sodium chloride). Next a blocking step was conducted where tissue
was incubated for 20 minutes in KPBS containing 1% bovine serum albumin (BSA), .4% triton-x
and 4% goat serum. Next the tissue was incubated in the primary antibody solution dilution of
1:60,000 which contained KPBS, 1% BSA, .4% triton-x, 1% goat serum and rabbit anti-GFAP
dilution of 1:1,500 overnight at 4⁰C. The next day, incubation continued in the primary antibody
at room temperature for an additional 2 hours. Tissue was rinsed 10X for 10 minute intervals in
KPBS containing with .25% BSA and .02% triton-x. Another incubation period followed in the
secondary antibody for 60 minutes at room temperature, solution contained KPBS, 1%
BSA, .02% triton-x and secondary antibody (goat-anti-rabbit, 33.33µl in 50 ml). Tissue was
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rinsed again 4X for 15 minutes intervals in KPBS with .25% BSA. Tissue was incubated in an
avidin: biotin: peroxidase complex (Vector Elite kit) for 1 hour with KPBS, 1% BSA and a 50/50
mixture of reagents A & B. Tissue was rinsed again in plain KPBS 2X for 10 minute intervals,
then again in Acetate-imidizole buffer solution (D2H2O, 1M sodium acetate and .2M imidazole)
2X for 10 minute intervals. Tissue was developed in Chromagen solution for 2-10 minutes was
deactivated using bleach. Chromagen solution contained D2H2O, 1M sodium acetate, .2M
imidazole, Nickel II sulfate and DAB stock solution (10 mg/ml). Final rinses were done in
acetate-imidazole buffer 2X for 10 minute intervals and then in buffered saline 2X for 10
minutes and then left in buffered saline until mounted and coverslipped. Stained sections were
viewed with an Olympus BX-51 microscope with a microfire camera by Optotronics. Astrocytes
were traced using a 60X/1.42 oil lens and Neurolucida software (MicroBrightfield, Inc.).
Glutamate Transporter 1 (GLT-1)
One series of sections from each animal were immunostained for astrocyte glutamate
transporter expression using the polyclonal antibody AB1783 antibody against GLT-1
(Millipore, Billerica, MA, USA) using guinea pig anti-GLT1 as the primary antibody and a
dilution of 1:350 with a goat-anti-guinea pig as the secondary antibody. All tissues were
exposed using a nickel sulfate-intensified diaminobenzidine (DAB) chromagen reaction.
All procedural steps for immunohistochemistry were the same with the exception of the
primary and secondary antibodies. In order to measure GLT-1 expression, hippocampal staining
density was quantified by optical density (arbitrary units) via binary monochrome micrographs in
Image J (Image processing and analysis in Java). The amount of illumination was kept constant
during photomicroscopy by activating the photoillumination lock function on the microscope. A
section that had coordinates between -2.8 and -4.3 posterior to bregma (Paxinos & Watson,
1982) were used and photos of the hippocampus were taken from each section at the same
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magnification (10X) which allowed for both the DG and CA1 regions to be visualized. Those
photos were then turned into binary density photos and the area of immunoreactivity was
calculated. Image J software microscope set-up contains a Microfire camera with a Nikon base
and lens Eclipse E400 with a Plan 10X/0.25 lens. Process performed entailed subtracting the
background, enhancing the contrast, making the picture binary and then quantifying using area
measurement.
Behavioral Tests
Morris Water Maze:
The water maze apparatus consisted of a 5 foot diameter water maze filled with water
made opaque by non-toxic paint. One quadrant of the water maze contained a goal platform
sunk approximately 3 cm beneath the surface. Animals were placed at pseudorandom locations
within the water maze and allowed to swim for 2 minutes or until they found the hidden goal
platform on each trial. Animals received three consecutive trials for each of the 4 days of
testing, with an inter-trial interval of one minute. Latency to escape to the platform on trial days
was recorded for each trial, and the median latency for each trial block was analyzed. After the
last trial on the fourth day the hidden goal platform was removed and an analysis of how much
time was spent in the goal quadrant was measured indicating retention of the goal platform
location. For this trial, animals were placed back into the maze at least one hour after their
acquisition trials and were allowed to search for the platform for 30 seconds.
Light/Dark Exploration Task:
The light-dark exploration task used a box that was divided into two sides, one white and
uncovered and the other black and covered. Animals were placed into the light side and allowed
to explore the box for 5 minutes. The proportion of time in the dark side was used as a measure
of the animal’s level of anxiety. A high proportion of time spent in the dark, covered side
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suggested preservation of anxiety.
Open Field Locomotion Task:
To control for general locomotion and exploratory drive, a potential confound in our
tasks, animals were placed in the middle of an open field and allowed to explore for 6 minutes.
The open field was 3 feet x 3 feet square and was divided into 9 equally sized grids. The number
of grids crossed during the trial was used as a measure of the animal’s locomotor activity.
Quantification of Astrocytes
GFAP-stained astrocytes from two regions of interest (the dentate gyrus [DG] and CA1)
in the hippocampus were quantified for all animals. Throughout the process of reconstruction
and quantification the researcher was blinded to the animal number and the treatment group. All
slides were coded by other members of the team or laboratory. After all quantifications were
finished the animal number and group assignments were provided. 18 astrocytes were
reconstructed, using neurolucida software for each animal. More particularly, ten astrocytes were
reconstructed in the dentate gyrus region of the hippocampus beginning in the hilus and moving
outward toward CA2. In the CA1 region, eight astrocytes were reconstructed from each animal
starting from the same point (above but relative to hilus)medially to laterally every whole
astrocyte encountered was traced until the pre-determined amount was acquired. A section that
had coordinates between Interaural 6.2mm Bregma -2.8 and Interaural 4.7mm Bregma -4.3
(Paxinos & Watson, 1982) were used for astrocyte tracing. Initially the region of interest (CA1
or dentate gyrus) was located and centered under 4X/0.10/-FN22 (Plan N Olympus lens), then
immersion oil was placed and the lens was switched to 60X/ 1.42 an oil lens ∞/0.17/FN26.5
(Plan APO N Olympus lens) where the astrocytes were selected, reconstructed and analyzed. The
dentate gyrus was done first and 10 astrocytes total were reconstructed for each animal; whereas
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8 were located and reconstructed in the CA1 region. Each VEGF treatment condition consisted
of 8 animals with 3 in each non-seized group and 5 in each seized group. Once all 18 astrocytes
were reconstructed using Neurolucida software (Microbrightfield, Inc.) both Branched structure
and Sholl analyses were performed and Neuroexplorer was used to provide a detailed description
of each astrocyte with a focus on measures that would be reflective of size and complexity of
process development. The mean (for normally distributed parameters) or the median (for nonGaussian parameters) was calculated for all sampled astrocytes per animal per region, the
measured parameters included soma size, astrocyte surface volume, length of processes, number
of nodes, number of intersections, diameter of processes, as well as roundness and tortuosity.
Additionally, the diameter, volume, and number of intersections by order of process branching
were analyzed to reveal information more pertinent to branching complexity, and these
parameters were all measured by either Branched structure or Sholl analyses. The following
parameters were measured via a Branched Structure Analysis (BSA): cell soma area, length tree
total, average diameter and volume tree total were considered a measure of cell size. Also in
BSA: mean length, number of processes, node count, base order for diameter at order 1 and order
2, volume at Orders 1-3 and terminal quantity were considered to measure complexity or process
development. Furthermore, the aspect ratio was quantified for each group and compared and
defined as a measure of roundness. . In addition, a Sholl analysis was performed to examine the
number of intersections with each concentric circle 5 microns apart in radius as moving away
from the soma center; order of primary versus secondary and tertiary processes (with primary
processes defined as those emerging from the cell soma area) whereas the subsequent orders
were secondary, tertiary, and quarternary, respectively; level of complexity, in which the
processes emerged from the cell soma at several levels of 5 micron radius.

41
Finally, the mean distance between adjacent astrocytes was measured in pseudorandomly
selected microscope fields by measuring the distance from the center of each astrocyte to its
nearest neighbor using a quick line measure in Image J software (NIH). In addition to
calculating the mean distance between astrocytes for each animal, the variability in the distances
was measured using the standard deviation as a measure of regularity of astrocyte spacing in
each animal. That is, those animals with higher standard deviations would show less regular
spacing of astrocytes (i.e. spacing favoring clustering) whereas those with lower standard
deviations would show regular spacing of astrocyte.

Figure 3. Shows a diagram of a reconstructed astrocyte from the CA1 region that highlights the
areas that were measured.
Statistical Analyses
For most measures, a 2 (VEGF vs. inactivated VEGF) X 2 (pilocarpine vs. vehicle)
independent groups factorial ANOVA was performed to order to compare differences between
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the groups as well as interactions between VEGF treatment and seizures. In the case of
interastrocyte distance and shape student t tests were performed to measure any differences
between VEGF treatment groups in seized animals given the difficulty in some animals in nonseized groups which did not show as much immunoreactivity. For measures which contained a
repeated measures variable such as trial in water maze acquisition and in branch order in the
branch structure and Sholl analyses a mixed model factorial ANOVA was conducted to quantify
any changes resulting from the independent variable group conditions. In each case, significant
interactions were further probed with a Scheffe post hoc test for simple main effects. All
analyses were performed using SPSS software, and significance was set at α=0.05.
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RESULTS
Behavioral Data
Morris Water Maze:
Learning and memory were analyzed using a modified Morris Water Maze. Data were
analyzed using a 2 (VEGF treatment) X 2 (seizure) x 4 (trial block) mixed model factorial
ANOVA. Treatment groups consisted of VEGF treated animals vs. inactivated VEGF control
animals as one independent variable and pilocarpine-induced status epilepticus vs. saline controls
as a second independent variable and trial blocks with latency to escape as the repeated measures
variable. Results revealed an overall significant difference in learning between treatment groups
(F (1, 70) =4.717, p=.033). Post hoc analyses revealed VEGF-treated seized animals showed
significant improvement when compared to inactivated VEGF seized controls using Tukey’s
LSD. This preservation of behavior was only partial as VEGF treated animals took significantly
longer to find the platform when compared to non-seized animals. Additionally, swim speed was
estimated using mean quadrant crossing time to ensure that increased latencies to escape did not
reflect decreased swim speed. Swim speed analysis revealed no significant difference between
non-seized controls and VEGF seized animals (mean difference=.048, SEM=.31, p=.121)
supporting the idea that swim speed was not likely to contribute to differences in latency to
escape.
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Figure 4. A two-way mixed model factorial ANOVA revealed that VEGF-treated animals
demonstrated partial preservation of learning and memory in the Morris Water Maze when
compared to animals treated with inactivated VEGF. VEGF treated animals showed decreased
latency to escape when compared to animals treated with inactivated VEGF. However, VEGF
treated animals did not perform as well as VEGF-saline or control-saline animals.
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Light/Dark Exploration Task:
The number of transitions and time spent in the dark compartment were analyzed using a
2 (VEGF treatment) x 2 (seizures) independent groups Factorial ANOVA with post-hoc
comparisons as appropriate. Results showed a significant effect of pilocarpine (F(1,70)=7.829,
p=.007) such that pilocarpine-treated animals spent significantly less time in the dark covered
side of the apparatus, suggesting they were less anxious than animals who did not receive
pilocarpine-induced SE. VEGF treatment had no significant effect on behavior in either seizure
group (F(1,70)=.008, p=.928).

Time spent in dark chamber (Sec)

Total Time in Dark Chamber
300

**

250
200
150
100
50
0

Inactive VEGF Saline
VEGF Saline
Inactive VEGF Pilo
VEGF Pilo

Figure 5. A One-way ANOVA resulted in a significant homogeneity test and therefore the
corrected model of between-subjects effects was used and pairwise comparisons were done using
a Tukey’s LSD to determine which treatment groups were significantly different. Results from a
one-way ANOVA revealed an overall significant difference in the amount of time spent in the
dark chamber between groups (F (4, 66) =4.95, p= .002). Post hoc analyses revealed a significant
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decrease in normal anxiety behavior in animals receiving pilocarpine and inactivated VEGF
treatment when compared to animals receiving pilocarpine and VEGF protein.
Grid Locomotor Task:
Grid crossings on the open field were analyzed using a 2 (VEGF treatment) x 2 (seizures)
independent groups Factorial ANOVA with post-hoc comparisons as appropriate. Results
revealed no significant differences among experimental groups (F (3, 70) =2.080, p=.111) in
relation to the amount of locomotor activity.

Figure 6. A two-way Factorial ANOVA revealed no significant differences among experimental
groups in relation to the amount of locomotor activity.
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All 10 Dentate Gyrus
astrocytes for each
animal were
pseudorandomly chosen

All 8 CA1 astrocytes for
each animal were
pseudorandmly chosen

Figure 7. Hippocampus at lower magnification (4X/0.10) showing GFAP expression
differences in animals that reached status epilepticus or did not seize after either VEGF protein
or Inactivated VEGF control.

Figure 8. Hippocampus at higher magnification (60X) showing GFAP expression differences in
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animals that reached status epilepticus or did not seize after either VEGF protein or Inactivated
VEGF control.
Astrocyte Morphology
Interastrocyte distance
VEGF significantly increased inter-astrocyte distance in both regions measured
regardless of treatment (see Figures 9 &10). The line measure function from Image J was used to
measure from the center of one astrocyte soma to the center of the nearest neighboring astrocyte
soma as a reflection of inter-astrocyte distance and may reveal the changes observed such that
astrocytes appeared more clustered. VEGF treatment resulted in a significant increase in interastrocyte distance when measured from soma to soma between neighboring astrocytes, indicating
that VEGF seemed to preserve the non-overlapping domain of astrocytes in the CA1 region
(t(5)=-57.02, p=.001) in seized groups. However, no significant effect was found in the DG
region (t (5) =-21.37, p=.081). Due to the complexity of cells, and their circuitry, in this region it
is possible that a larger sample size may have been needed in order to detect any patterns of
change based on VEGF.
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Figure 9. An independent groups Student’s t test shows mean distance between neighboring
astrocytes measured one month after status epilepticus is significantly higher in animals treated
with VEGF during status when compared to treatment with inactivated VEGF in the CA1 region
of the hippocampus. As there was less GFAP expression in saline groups it was very difficult to

Mean distance between astrocytes
(µm)

find neighboring astrocytes in specific fields.

Interastrocyte Distance of Pilocarpine-seized
Animals in Hippocampal Dentate Gyrus Region
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Figure 10. No significant difference was found between VEGF and inactivated VEGF treated
animals in the dentate gyrus. Cells in this region are highly variable and may make it difficult to
detect a consistent pattern.
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Astrocyte Morphology
Inactivated VEGF

VEGF

No seize

Seize

Figure 11. Shows the average astrocyte of the 8 astrocytes traced in CA1 region for each
experimental condition.
CA1 Region
Size: VEGF treatment during SE significantly prevented post-SE increases in astrocyte cell body
area (effect of VEGF: F(1,12)= 7.438, p=.018; effect of Pilocarpine: F(1,12)=11.912, p=.005;
interaction: F(1,12)=7.940, p=.016, see figure 13) and volume (effect of VEGF:
F(1,12)=16.708,p=.002; effect of pilocarpine: F(1,12)=35.065, p=.001; Interaction
F(1,12)=13.356,p=.003, see figure 14). A significant interaction effect of VEGF by pilocarpine
was found for total astrocyte process length (F(1,12)=6.07, p=.030), such that VEGF prevented
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the increases in length induced by status epilepticus (see figure 15). Pilocarpine treatment
significantly increased average astrocyte process diameter (F(1,12)=4.920, p=.047, see figure 16)
but VEGF did not change this effect. In addition, there was no interaction between the VEGF
and pilocarpine treatments for average diameter F(1,12)=.189, p=.671. These findings suggest
that although there were significant differences in size as a result of pilocarpine and/or VEGF
treatment but differences in shape did not reach statistical significance. Additionally, aspect ratio
was quantified and there were no statistically significant differences for the CA1 region as an
effect of pilocarpine (F(1,12)=2.70, .126) or as an effect of VEGF treatment
(F(1,12)=2.54, .137). However there was a trend in CA1 for the interaction of pilocarpine and
VEGF treatment (F(1,12)=4.57, .054) suggesting that astrocytes in the pilocarpine group
receiving VEGF treatment were more oblong than any other group. Furthermore, aspect ratio
showed no significant effect of pilocarpine (F(1,12=.243, .631), VEGF treatment
(F(1,12)=.204, .660) or interaction between pilocarpine and VEGF treatment
(F(1,12)=.562, .468) in the dentate gyrus region suggesting a change in size but not shape.
Size
Inactive
CA1
VEGF/Saline
Soma
Area
11.130
Total
Length
25.906
Average
Diameter
0.316
Total
Volume
13.917

SEM

Inactive
VEGF/Pilo SEM

VEGF/Saline SEM

VEGF/Pilo

SEM

2.400

53.438 11.788

11.844 2.037

16.965 2.069

5.677

37.797

2.917

27.469 2.456

23.154 0.598

0.001

0.928

0.328

0.259 0.030

0.670 0.193

1.659

85.620

9.448

10.675 2.843

27.649 9.656

Table 3. Shows all measures of size for the CA1 region of the hippocampus that includes soma
area, total process length, average process diameter and average total volume.
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Inactivated VEGF

VEGF protein

No Seize

Seize

Figure 12. Shows the average astrocyte of the 10 astrocytes traced in dentate gyrus region for
each experimental condition.
DG region Size: VEGF treatment during SE significantly prevented post-SE increases in
astrocyte cell body (effect of VEGF F(1,12)=11.414, p=.05), Pilocarpine (F(1,12)=15.952,
p=.002) and an Interaction effect of VEGF by pilocarpine (F(1,12)=8.488, p=.013, see figure
13). A similar effect of VEGF was observed for average diameter of processes (VEGF
F(1,12)=13,186, p=.003), Pilocarpine (F(1,12)=20.713, p=.001) and Interaction of VEGF by
pilocarpine (F(1,12)=8.458, p=.013, see figure 16). VEGF produced a similar effect on astrocyte
volume (VEGF F(1,12)=7.675, p=.017), Pilocarpine (F(1,12)=5.415, p=.038), except that the
interaction effect of VEGF by pilocarpine did not achieve significance (see figure 14). In
contrast, neither VEGF (F(1,12)=.230, p=.640) nor pilocarpine (F(1,12)=.553, p=.471) produced
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a significant effect on astrocyte process length in the dentate gyrus (see figure 15).

Inactive
Inactive
Size DG VEGF/Saline SEM
VEGF/Pilo SEM
VEGF/Saline SEM VEGF/Pilo
Soma
Area
18.223
7.978
53.820 5.420
15.657 3.295
21.426
Length
Total
24.546
1.239
29.683 2.864
26.364 2.329
25.262
Average
Diameter
0.389
0.099
1.180 0.130
0.313 0.023
0.490
Volume
Total
23.896 12.679
70.629 14.725
14.625 2.345
19.024

SEM
2.610
2.868
0.130
2.106

Table 4. Shows all measures of size for the dentate gyrus region of the hippocampus that
includes soma area, total process length, average process diameter and average total volume.

100

Soma Area

90

Mean cell body area

80

X
**

X
#

***

##

70
60

Inactivated VEGF Saline

50

VEGF Saline
Inactivated VEGF Pilo

40

VEGF Pilo

30
20
10
0
CA1

DG

Figure 13. Pilocarpine-induced SE resulted in significant increases in soma area of the
astrocytes in both the CA1 and DG regions of the hippocampus. VEGF treatment significantly
reduced the increase in soma area of astrocytes in both CA1 and DG regions of the hippocampus
suggesting alterations typically observed following SE are attenuated by VEGF treatment.
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Symbols: Pilocarpine effect * p<.05, ** p<.01, VEGF effect # p<.05, ## p<.01, significant
(p<.05) interaction effects between variables are indicated by an X.
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Figure 14. Pilocarpine-induced SE resulted in a significant increase in the total volume of the
astrocytes in both the CA1 and DG regions of the hippocampus. VEGF treatment significantly
attenuated the pilocarpine-induced changes in volume in both CA1 and DG regions. Symbols:
Pilocarpine effect * p<.05, ** p<.01, VEGF effect # p<.05, ## p<.01, significant (p<.05)
interaction effects between variables are indicated by an X.
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Figure 15. A significant interaction was found between VEGF and pilocarpine treatments
In CA1 region of the hippocampus such that pilocarpine increased length and VEGF treatment
prevented this effect in seized animals. Significant (p<.05) interaction effects between variables
are indicated by an X.
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1.2
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1

Inactive VEGF Pilo

0.8

VEGF Pilo

0.6
0.4
0.2
0
CA1
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Figure 16. Pilocarpine treatment significantly increased the average process diameter in both the
CA1 and DG regions of the hippocampus, however VEGF treatment did not significantly
attenuate this change in the CA1 region. Symbols: Pilocarpine effect * p<.05, ** p<.01, VEGF
effect # p<.05, ## p<.01, significant (p<.05) interaction effects between variables are indicated
by an X.
CA1 Region
Complexity: Measures reflecting astrocyte branch complexity such as node count revealed
significant effects of both VEGF (F(1,12)=7.117, p=.020) and pilocarpine (F(1,12)=6.833,
p=.023) such that pilocarpine leading to status significantly increased complexity across
measures, whereas VEGF decreased complexity (see figure 19). In addition, there was a
significant interaction between VEGF and pilocarpine treatments such that VEGF consistently
attenuated the increased complexity induced by pilocarpine-induced status (F(1,12)=5.347,
p=.039). Other measures of complexity showed a similar pattern of effects as that described for
node count as follow: volume at Order 1 revealed a significant effect of VEGF (F(1,12)=14.592,
p=.002) and pilocarpine (F(1,12)=37.343, p=.001) and an interaction effect between the two
(F(1,12)=10.310, p=.007); volume at Order 2 a significant effect of VEGF (F(1,12)=17.906,
p=.001) and pilocarpine (F(1,12)=29.921, p=.001) and an interaction between the two
(F(1,12)=13.814, p=.003); volume at Order 3 a significant effect of VEGF (F(1,12)=8.514,
p=.013) and pilocarpine (F(1,12)=25.756, p=.001) and an interaction between the two
(F(1,12)=8.972, p=.011) (see figures 22 & 23).
The total number of processes revealed a significant effect of VEGF such that VEGF
decreased the total number of processes regardless of seizure status (F(1,12)=6.833, p=.023) (see
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figure 18). In contrast, VEGF did not significantly affect mean length (see figure 17), however
the interaction between VEGF and pilocarpine showed a statistical trend consistent with those
observed for other measures of complexity (F(1,12)=4.185, p=.063). Additionally, no effect of
VEGF was found at base diameter at orders 1 or 2 (see figures 20 & 21), whereas Pilocarpine
significantly increased mean length (F(1,12)-6.902, p=.022), base diameter at order 1
(F(1,12)=9.114, p=.011), and base diameter at order 2 (F(1,12)=8.454, p=.013). No significant
effect was found for either VEGF or pilocarpine when measuring Terminal quantity. Together
these results suggest that VEGF is attenuating many, but not all, parameters that are normally
altered following seizures.
Complexity Inactive
CA1
VEGF/Sal
Mean
4.557
Length
Node
3.500
Count
Number of
6.042
Processes
Vol Order
8.190
1
Vol Order
4.685
2
Vol Order
0.916
3
Diameter
0.212
Ord 1
Diameter
0.466
Ord 2

SEM

Inactive
VEGF/Pilo SEM

VEGF/Sal SEM

VEGF/Pilo SEM

1.232

13.167

0.735

5.269

2.336

6.340

1.987

0.433

7.162

0.674

3.236

0.617

3.460

1.083

0.397

5.625

0.402

5.721

0.575

7.665

0.180

0.418

32.940

3.061

6.573

1.524

14.273

3.704

1.660

36.727

4.445

2.889

1.000

9.005

4.390

0.504

11.686

1.805

1.019

0.564

3.795

1.805

0.014

0.297

0.027

0.203

0.027

0.289

0.030

0.062

1.482

0.342

0.388

0.055

0.761

0.158

Table 5. Shows all measures reflecting complexity in CA1 region of the hippocampus including
mean length of processes, node count, number of processes, process volume by branching order
and process diameter by branching order.
DG Complexity: Measures reflecting branch complexity in the dentate gyrus showed
similar patterns as those reported for CA1, albeit less striking, such as for volume at Order 1 a
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significant effect of VEGF (F(1,12)=11.890, p=.005) and pilocarpine (F(1,12)=11.327, p=.006)
as well as an interaction effect of VEGF by pilocarpine (F(1,12)=8.492, p=.013); volume at
Order 2 a significant effect of VEGF (F(1,12)=5.982, p=.031); volume at Order 3 a significant
effect of VEGF (F(1,12)=8.550, p=.013); node count a significant effect of VEGF
(F(1,12)=5.254, p=.041), but no significant effect of Pilocarpine (F(1,12)=.023, p=.882) or
interaction effect (F(1,12)=.118, p=.737). A significant effect of Pilocarpine was found for mean
length (F(1,12)-13.305, p=.003), with no significant effect of VEGF alone and a statistical trend
for the interaction between the two (F(1,12)=4.30, p=.060). For base diameter at order 1 there
was a significant effect of Pilocarpine (F(1,12)=13.090, p=.004) but no effect of VEGF and at
base diameter at order 2 a significant effect of VEGF (F(1,12)=8.611, p=.012) and Pilocarpine
(F(1,12)=8.602, p=.013) but no significant interaction effect. No significant effect was found for
Pilocarpine (F(1,12)=1.883, p=.195) or VEGF (F(1,12)=.535, p=.479) when measuring Terminal
quantity.
Complexity
DG
Mean
Length
Node
Count
Number of
Processes
Volume
Order 1
Volume
Order 2
Volume
Order 3
Diameter
Order 1
Diameter
Order 2

Inactive
VEGF/Sal SEM

Inactive
VEGF/Pilo SEM

VEGF/Sal SEM

VEGF/Pilo SEM

3.668 0.359

13.548

0.735

4.456

1.938

7.174

2.959

5.408 1.501

5.240

0.507

3.100

0.785

3.533

0.467

7.058 0.412

6.733

0.384

6.180

0.403

7.580

0.676

11.809 4.476

36.120

4.909

9.741

1.821

11.489

0.992

8.477 5.222

24.212

6.329

3.817

0.925

5.970

0.876

2.424 1.871

6.364

1.215

0.933

0.523

1.279

0.383

0.188 0.031

0.351

0.400

0.202

0.013

0.259

0.004

0.602 0.202

1.033

0.107

0.333

0.083

0.602

0.067

Table 6. Shows all measures reflecting complexity in dentate gyrus region of the hippocampus
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including mean length of processes, node count, number of processes, process volume by
branching order and process diameter by branching order.

Mean Length
*

Length divdided by number of
branches

18

**

#

16
14
12

Inactive VEGF Saline

10

VEGF Saline

8

Inactive VEGF Pilo

6

VEGF Pilo

4
2
0
CA1

DG

Figure 17. Pilocarpine treatment significantly increased the length of primary, secondary, and
tertiary order branches. VEGF significantly reduced the length at these orders of process
branching in the CA1 region. Symbols: Pilocarpine effect * p<.05, ** p<.01, VEGF effect #
p<.05, ## p<.01.

Number of Processes
#

Mean number of processes

9
8
7
6

Inactive VEGF Saline

5

VEGF Saline

4

Inactive VEGF Pilo

3

VEGF Pilo

2
1
0
CA1

DG
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Figure 18. VEGF significantly attenuated the number of processes in the CA1 region of
The hippocampus. No significant results were found in the DG region of the hippocampus.

Node Count

X
*

9

#

mean number of nodes

8

#

7
6

Inactive VEGF Saline

5

VEGF Saline

4

Inactive VEGF Pilo

3

VEGF Pilo

2
1
0
CA1

DG

Figure 19. Pilocarpine treatment significantly increased the mean number of nodes in
the CA1 region of the hippocampus and VEGF treatment significantly attenuated this change.
Additionally, VEGF significantly decreased the number of nodes in the DG region of the
hippocampus in seized animals. Symbols: Pilocarpine effect * p<.05, ** p<.01, VEGF effect #
p<.05, ## p<.01, significant (p<.05) interaction effects between variables are indicated by an X.

Mean diameter at two orders of
branching (µm)

Base Diameter CA1
3

^ X

2.5
2

Inactive VEGF Saline
VEGF Saline

1.5

Inactive VEGF Pilo

1

VEGF Pilo
0.5
0
Order 1
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Figure 20. A statistical trend was found at order 2 in CA1 region of the hippocampus, as
indicated by a ^, between VEGF and inactivated VEGF animals that seized, such that VEGF
decreased mean diameter. significant (p<.05) interaction effects between variables are indicated
by an X.

Base Diameter in DG
Mean diameter at two orders of
branching (µm)

1.8
1.6

**

##

1.4
1.2

Inactive VEGF Saline

1
0.8

VEGF Saline

**

Inactive VEGF Pilo

0.6

VEGF Pilo

0.4
0.2
0
Order 1

Order 2

Figure 21. A significant effect of pilocarpine was found in the diameter of order 1 branches in
the DG region of the hippocampus but VEGF had no significant effect on this change. However,
at order 2 there was a significant effect of pilocarpine such that there was an increase in diameter
and VEGF treatment significantly decreased the diameter in seized animals. Symbols:
Pilocarpine effect * p<.05, ** p<.01, VEGF effect # p<.05, ## p<.01, significant (p<.05)
interaction effects between variables are indicated by an X.
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CA1
Mean volume at three orders of
branching (µm³)

50
45

X
**

X
##

**

##

40
35

X
** ##

30

Inactive VEGF Saline

25

VEGF Saline

20

Inactive VEGF Pilo

15

VEGF Pilo

10
5
0
Volume Order 1 Volume Order 2 Volume Order 3

Figure 22. There was a significant effect of pilocarpine on increasing mean branch volume at all
three orders. A significant effect of VEGF treatment was also found at all three orders of volume
showing that VEGF treatment significantly decreased volume in seized animals. An interaction
between the two variables was found at all three orders. Symbols: Pilocarpine effect * p<.05, **
p<.01, VEGF effect # p<.05, ## p<.01, significant (p<.05) interaction effects between variables
are indicated by an X.
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Dentate Gyrus

X
**

Mean volume at three orders of
branching (µm³)

45

##
^

40

#

35
30

Inactive VEGF Saline

25

VEGF Saline

20

Inactive VEGF Pilo

#

15

VEGF Pilo

10
5
0
Volume Order 1 Volume Order 2 Volume Order 3

Figure 23. Pilocarpine significantly increases branch volume at order 1 and produced a statistical
trend toward a difference at order 2 without affecting order 3 volumes. A significant effect of
VEGF treatment on volume was found at all three orders such that VEGF treatment significantly
decreased volume in seized animals. An interaction between the two variables was found at order
1. Symbols: Pilocarpine effect * p<.05, ** p<.01, VEGF effect # p<.05, ## p<.01, significant
(p<.05) interaction effects between variables are indicated by an X. and a statistical trend as ^.
Sholl Analysis
A Sholl analysis was conducted to determine branch characteristics at different orders
or distances from the astrocyte cell bodies. This analysis revealed a significant increase in the
number of intersections in animals receiving pilocarpine-induced SE when compared to nonseized animals (Λ = .041, F(1/12)=14.749, p=.004). Seized animals receiving inactivated VEGF
demonstrated significantly more intersections when compared to those in the VEGF or the nonseized groups. A significant effect of VEGF treatment revealed (Λ=.090, F(1 ,12 )= 6.289 ,
p=.029),that less branching occurred at an earlier order from the soma in animals treated with
active VEGF when compared to inactivated VEGF in pilocarpine-induced seized group. An
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interaction effect between Pilocarpine and VEGF was also found, reflecting that VEGF
prevented or attenuated the increases observed with pilocarpine (Λ=.085, F(1,12)=6.755,
p=.025).
12

Sholl Intersections

Mean Number of intersections

10

8
IV saline
6

VEGF saline
IV pilo

4

VEGF pilo

2

0
CA1

DG

Radius 5

CA1

DG

Radius 10

CA1

DG

Radius 15

Figure 24. A Sholl analysis revealed a within subjects effect of number of intersections at
various radius locations as moving from the soma outward in CA1 region of significant
interaction with pilocarpine (Λ = .041, F(1/12)=14.749, p=.004), significant interaction with
VEGF (λ=.090, F(1,12 )= 6.289, p=.029) and a triple interaction with the two independent
variables (Λ=.085,F(1,12)=6.755, p=.025); between subjects effects revealed no significant
effect of pilocarpine (F(1,12)=1.231, p=.289), a significant effect of VEGF (F(1,12)=4.465,
p=.053) and no interaction between the two (F(1.12)=3.895, p=.072). For DG region within
subjects effects showed no significant interaction with pilocarpine (Λ=.143 F(1.12)=3.757,
p=.081) and a significant interaction with VEGF (Λ=.016 F(1,12)=39.016, p=.016) and no triple
interaction (Λ=.382 F(1,12)=1.011, p=.520); between subjects effects showed no significant
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effects of pilocarpine (F(1,12)=.641, p=.439), VEGF (F(1,12)=3.445, p=.088) and no interaction
between the two (F(1,12)=.471, p=.506). Symbols: Pilocarpine effect * p<.05, ** p<.01, VEGF
effect # p<.05, ## p<.01, significant (p<.05) interaction effects between variables are indicated
by an X.

Figures 25 a,b,c&d. The results of a Sholl Analysis are shown with each treatment group
represented in a separate graph to better reveal process patterning. Inactivated VEGF treated
animals that seized are represented by the red line and VEGF treated animals that seized are
represented by the blue line in the graphs below. Inactivated controls are represented by the
purple line and VEGF treated controls are represented by the green line. This is a measure of the
process length at each order. Primary processes were defined as those emerging from the cell

66
soma area whereas subsequent orders were secondary, tertiary, quarternary respectively (Orders
2-4). Showing VEGF attenuates seizure-induced pathological branching complexity; whereas
inactivated VEGF controls appeared to demonstrate an increase in branching complexity in the
CA1 region of the rat hippocampus. An ANOVA test was performed using increments of 5
microns in each Radius.

Glutamate Transporter (GLT-1) Expression:
GLT-1 expression was measured by optical density via binary monochrome micrographs
(40X) in both CA1 and the dentate gyrus regions of the hippocampus. A between subjects 2
(VEGF treatment) X 2 (seizure) ANOVA revealed no significant effects of pilocarpine or VEGF
treatment on their own, but the interaction between the two variables showed a statistical trend
(F(1,17)=4.289, p=.054, see figure 22) for . However, in the dentate gyrus region pilocarpine
showed a statistical trend toward decreasing Glt-1 expression (F(1,17)=3.591, p=.075, see figure
22). There was no significant effect of VEGF treatment. It is possible that due to the nature of the
variability of the cells and structure, as well as the complex connectivity within the hilus, more
animals will need to be quantified to reveal statistically significant results in this region.
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GLT-1 Expression
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Figure 26. Optical density measurements for GLT-1 immunoreactivity showed no significant
effect of any of the treatments on Glt-1 expression, although there was a statistical trend toward
an effect of pilocarpine decreasing Glt-1 expression in the dentate gyrus.
Correlations Between Astrocyte Parameters and Behavior:
Correlation analyses revealed a significant relationship between measures of size and
complexity of the astrocytes and the performance of the animals in the water maze for both
measures of acquisition and retention (see Tables 7-14 for statistics and details). Results suggest
that the pilocarpine-induced changes in measures of size and complexity, which were attenuated
by VEGF, significantly correlated with the partial behavioral preservation observed in these
animals. Particularly, soma area, diameter and volume totals as well as measures of complexity
such as number of processes, node count, volume by order and in some cases diameter by order
were significant predictors of the behavioral measures reflecting learning and memory
preservation.
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Acquisition
Size CA1
Region
Latency
Block 4
Soma Area
CA1
Average
Diameter
CA1
Length total
CA1

Latency
Block 4

SA

Diameter

Length

Volume

1

0.849**

0.611**

0.402

0.922**

0.849**

1

0.548*

0.455*

0.895**

0.611**

0.548*

1

0.428

0.724**

0.402

0.455

0.428

1

0.639**

Volume
total CA1

0.922**

0.895**

0.724**

0.639**

1

Table 7. The correlation table shows the correlation coefficients between astrocyte size
measurements in the CA1 region of the hippocampus as predictors of learning acquisition in
MWM. Results show that size measures in CA1 were significantly positively correlated to
learning acquisition in MWM such that as the size of astrocyte increased so did the animal’s time
to find the platform. *p<.05, **p<.01, ***p<.001
Acquisition
Size DG
Latency
Block 4
Soma Area
DG
Average
Diameter
DG
Length
Total DG
Volume
Total DG

Lat bl 4

SA

Diameter

Length

Volume

1.000

0.690**

0.778**

.125

0.632**

0.689**

1.000

0.929**

.047

0.917**

0.778**

0.929**

1.000

.079

0.890**

.125

.047

.079

1.000

.153

0.632**

0.918**

0.890**

.153

1.000

Table 8. Correlation table shows the size measurements in DG region of the hippocampus as
predictors of learning acquisition in MWM. Results show that size measure in DG were
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moderately to strongly significantly positively correlated to learning acquisition in MWM such
that as the size of astrocyte increased so did the animal’s time to find the platform. *p<.05,
**p<.01, ***p<.001.

Acquisition LatBL4 ML
PC
CA1
Complexity
1 .652** .458*
LatBL4

NC

D1

D2

V1

V2

V3

.698** .761** .808** .913** .915** .865**

Mean
Length
Process Ct

.652**

1 .543*

.458*

.543*

Node Ct

.698**

.820** .591**

DiamOrd1

.761**

DiamOrd2

.808**

.709** .577** .830** .599**

VolOrd1

.913**

.810** .694** .844** .634** .867**

VolOrd2

.915**

.841** .641** .851** .624** .894** .983**

VolOrd3

.865**

.860** .597** .909** .673** .879** .925** .929**

0.402

.820**

0.402 .709** .810** .841** .860**

1 .591**

0.272 .577** .694** .641** .597**

0.272 .52*

1 .552*

.830** .844** .851** .909**
1 .599** .634** .624** .673**
1 .867** .894** .879**
1 .983** .925**
1 .929**
1

Table 9. Correlation table shows measures of complexity in CA1 region of the hippocampus as
predictors of behavioral learning acquisition in MWM. The following measures of complexity
were significantly related to the time to find the platform in acquisition trials such that as
measures of complexity were decreasing the time to find the platform decreased. VEGF-treated
animals demonstrated improved learning and significantly shorter times to find the platform over
the trial days when compared to animals that seized but received inactivated VEGF. This was
only partial preservation of learning behavior as VEGF treated animals also took significantly
longer to find the platform when compared to non-seized animals. *p<.05, **p<.01, ***p<.001.
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Acquisition
DG
Complexity
LatBL4

LatBL4 ML

PC

NC

D1

1

.587**

0.08

0.219

.771** .595** .692** .508*

1

0.242

0.094

.772** .699** .804** .700** .562**

Mean Length .587**

D2

V1

0.395

V2

V3

.629*

Process CT

0.08

0.242

1

0.355

0.132

0.362

Node Ct

0.219

0.094

0.355

1

0.011

.630** 0.379

DiamOrd1

.771**

.792**

0.132

0.011

1

.507*

.675** .485*

DiamOrd2

.595**

.699**

0.362

.630** .507*

1

.825** .892** .867**

VolOrd1

.692**

.804**

0.395

0.379

VolOrd2

.508*

.70**

.583** .671** .485*

.892** .902** 1

VolOrd3

.629**

.562**

0.437

.867** .857** .922** 1

.675** .825** 1

.704** .514*

.583** 0.437
.671** .704**
.514*

.902** .857**
0.922

Table 10. Correlation table shows measures of complexity in DG region of the hippocampus as
predictors of behavioral learning acquisition in MWM. The following measures of complexity
were significantly related to the time to find the platform in acquisition trials such that as
measures of complexity were decreasing the time to find the platform improved. VEGF treated
animals demonstrated improved learning and significantly shorter times to find the platform over
the trial days when compared to animals that seized but received inactivated VEGF. However,
this was only partial preservation of learning behavior as VEGF treated animals were also took
significantly longer to find the platform when compared to non-seized animals. *p<.05, **p<.01,
***p<.001.
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Retention CA1
Size

GQ

SA

D

L

V

Goal Quad

1

.-0.456*

-0.292

-0.14

.-0.608**

Soma Area

.-0.465 *

1

0.548*

0.455*

0.895**

Diameter

-0.292

0.548*

1

0.428

0.724**

Length

-0.14

0.455*

0.428

1

0.639**

Volume

.-0.608**

0.895**

0.724**

0.639**

1

Table 11. Correlation table showing astrocyte size measurements in the CA1 region of the
hippocampus as predictors of memory in the MWM. These measures were negatively correlated
such that as size measures decreased the time spent in the goal quadrant increased suggesting the
animals remembered the location of the platform better as astrocytes decreased in size. *p<.05,
**p<.01, ***p<.001.

Retention Size DG Goal Quadrant SA

D

L

V

Goal Quadrant

1

-0.259

-0.351

-0.052

-0.249

Soma Area

-0.259

1

.929**

0.047

.918**

Diameter

-0.351

.929**

1

0.079

.890**

Length

-0.052

0.047

0.079

1

0.153

Volume

-0.249

.918**

.890**

0.153

1

72
Table 12. Correlation table showing the size measurements in the DG region of the hippocampus
as predictors of memory in MWM. Measures were negatively correlated such that as size
measures decreased the time in the goal quadrant increased suggesting the animals remembered
the location of the platform better when the astrocytes were smaller. *p<.05, **p<.01,
***p<.001.
Retention
Complexity
CA1
Time Goal
Mean
Length
Process Ct
Node Ct

TG

ML

1

PC

-0.228

-0.228

1 .543*

.820**
0.402

DiamOrd1

D1

-0.337 .-.486*

-0.337 .543*
.-.486*

NC

.820**
1 .591**

.591**

D2

V1

V2

V3

..-.490*
.673**
0.402 .709**

..647**
.810**

.-.575*

.-.568*

.841**

.860**

0.272 .577*

.694**

.641**

.597**

.830**

.844**

.851**

.909**

1 .599**

.634**

.624**

.673**

1 .867**

.894**

.879**

1 .983**

.925**

1 .552*

0.272 .552*

.673**
.709**

.577*

.830**

.599**

.810**

.694**

.844**

.634**

.867**

.841**
-.575*
-.568** .860**

.641**

.851**

.624**

.894**

.983**

.579**

.909**

.673**

.879**

.925**

DiamOrd2
-.490*
VolOrd1
.647**
VolOrd2
VolOrd3

1 .929**
.929**

1

Table 13. Correlation table showing the complexity measurements in the CA1 region of the
hippocampus as predictors of memory in MWM. As size measures were decreased the time spent
in the goal quadrant increased. *p<.05, **p<.01, ***p<.001.
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Retention
DG

TG

ML

PC

NC

D1

D2

V1

V2

V3

Complexity
Time Goal
Quad

1.000

-.180

-.187

-.223

.-.448*

-.254

-.253

-.190

-.339

Mean

-.180

1.000

.242

.094

.792**

.699** .802** .700** .562*

-.187

.242

1

.355

.132

.362

-.223

.094

.355

1

.011

.630** .379

.-.448*

.792** .132

.011

1

.507*

.675** .485*

-.254

.699** .362

.630**

.507*

1

.825** .892** .867**

-.253

.804** .395

.379

.675**

.825** 1

-.190

.700** .583*

.671**

.485*

.892** .902** 1

-.339

.562** .437

.704**

.514*

.867** .857** .922** 1

Length
Process Ct

.395

.583*

.437

DG
Node CT

.671** .704**

DG
DiamOrd1

.514*

DG
DiamOrd2
DG
VolOrd1

.902** .857**

DG
VolOrd2

.922**

DG
VolOrd3
DG

Table 14. Correlation table showing the complexity measurements in DG region of the
hippocampus as predictors of memory in MWM. The measures of complexity were negatively
correlated with the behavior such that as size measures were decreased the time spent in the goal
quadrant increased. *p<.05, **p<.01, ***p,.001.
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Chapter 3: Discussion
Previous work from our laboratory showed that 2-4 weeks following pilocarpine-induced
seizures in animals that had received VEGF during status epilepticus had significantly improved
behavioral status when compared to those receiving inactivated VEGF (Nicoletti et al., 2010).
However, the VEGF-treated group showed no difference in neuronal loss in the hippocampus at
this time point, suggesting that VEGF's ability to preserve behavioral performance was unrelated
to direct neuroprotection (Nicoletti et al., 2008). The mechanisms underlying this transient
protection are currently unknown and warrant further investigation. However, the fact that
behavioral preservation occurred in the absence of continued neuronal preservation, suggests that
VEGF induced other enduring changes in the hippocampus that led to functional preservation.
VEGF treatment has a “quieting effect” on neurons, which appears to be independent of changes
in intrinsic neuronal properties (McCloskey et al., 2005), suggesting a potential contributory role
of circuit changes, or of other cells, in VEGF’s effects on hippocampal function.
Studies have proposed that other cell types contribute both to circuit function and seizure
activity in the hippocampus. For instance, astrocytes have calcium oscillations have the ability
to facilitate seizures and increases in astrocytic calcium are sufficient to cause local paroxysmal
depolarization (Tian et al., 2005). Reports have been accumulating regarding the possibility of an
astrocytic basis for epilepsy through Ca++-dependent glutamate release (Haydon, 2001; Ye et
al., 2003; Tian et al., 2005). In addition, some data suggests that disturbed astroglial receptor
function might contribute to pathological conditions and hyper-excitability in human epilepsy
(Seiffert et al., 2004).
Given that astrocytes have been reported to have VEGF receptors and to be VEGF
responsive, it is possible that administration of VEGF in our experiments altered astrocyte
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morphology and function.
Summary of Results
The current study measured astrocyte morphological and patterning parameters one
month after status epilepticus to understand whether changes in astrocytes treated with VEGF
would correlate with the functional improvements observed with VEGF treatment. Behavioral
results revealed a significant effect of seizures on Morris water maze (MWM) performance for
both acquisition and retention, such that seized animals showed a marked impairment in
performance as we have reported previously (Nicoletti et al., 2010). Also in agreement with our
previous results, VEGF significantly improved the MWM performance of pilocarpine-treated
animals, suggesting that it contributes to functional preservation. Seizures also significantly
impaired anxiety-like behaviors in the light-dark task, and but this impairment was not
significantly reversed by VEGF treatment in the current study as we have previously reported
(Nicoletti et al., 2010).
Unlike neuron counts (Nicoletti et al., 2010), astrocyte morphology was significantly
different in VEGF-treated animals one month after status epilepticus. Interastrocyte distances
were measured as a way to reflect if VEGF may be attenuating the overlapping among processes
frequently observed in astrocytes from seizure models and in human epilepsy. VEGF had a
significant effect in increasing the amount of distance between neighboring astrocytes,
suggesting that VEGF did prevent the loss of astrocytic domain organization observed in chronic
epilepsy. VEGF also significantly reduced the process branching complexity and the length the
processes reach at later orders. More particularly, VEGF reduced the number of branch orders
and the extension from the soma outward. This finding could suggest that VEGF is preventing
the processes from entering into the domains of other astrocytes, which may assist in preventing
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the spread of depolarization and or the release of glutamate under conditions of excitotoxicity. It
may also allow for more efficient information processing and therefore make behavioral
recovery more likely due to proper communication between endothelium, astrocytes, microglia
and therefore neurons.
Correlation and regression analyses using astrocyte size measures and process branching
complexity measures as predictors of both acquisition and retention in the water maze revealed a
significant negative correlation between process complexity and a positive correlation between
astrocyte size and cognitive parameters. These data suggest that larger, more branched astrocytes
were more likely to be associated with poor cognitive performance. Because treatment with
VEGF during SE reduced astrocyte size and complexity, VEGF treatment was also associated
statistically with improved cognitive performance. It is important to note that VEGF in this
study was no longer on board at the time of behavioral testing and that tissue was only taken
after the behavioral tests were completed in all cohorts. Therefore, it is not known if the changes
that we observed in astrocyte parameters were in place for the entire month after SE. That is, we
cannot say for certain whether VEGF itself led to these changes, whether withdrawal from
VEGF led to the changes, or whether alterations in hippocampal function and structure caused by
VEGF acutely led to lasting alterations in astrocyte and functional parameters. Additionally, we
cannot be sure if the astrocyte differences observed in the VEGF-treated group caused the
preservation of behavior or if other variables that were normalized in the system by VEGF also
prevent SE-induced changes to astrocytes. Furthermore, there were differences observed between
the CA1 and DG regions of the hippocampus with a higher variability found in the dentate gyrus
region when compared to the CA1 region. It is possible that this increased variability may be
explained by the differences in the cell variety and the differences in the complexity of the neural
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circuitry in these two regions For example, studies report some cells in the dentate gyrus fire in
multiple locations whereas other cells fire in a single location more similar to CA1 place cells
(Jung & McNaughton, 1993; Leutgeb et al., 2007) and these different firing patterns may lead to
more complex circuitry. Other possible explanations may involve the increased amount of
genesis that occurs in the dentate gyrus and the age of the cells in this location. Therefore, it may
be interesting to investigate the age of the astrocytes using markers such as glutathione transport
or D-serine racemase which are only found in mature astrocytes but not mature NG2+ cells or
young astrocytes (Parpura & Haydon, 2009).
Astrocytes and Hippocampal Function
Astrocytes serve many roles that may be compromised following SE or chronic seizures
and are crucial to proper CNS communication. For instance, tight astrocyte end feet junctions
form the BBB and a link to neurons, balance of water via AQP4 channels, proton shuffling such
as Na+/H+, clearance of glutamate and K+ from extracellular space, glutamate conversion to
glutamine, secretions such as thrombospondin for synapse formation, gap junction networks that
allow for transport of important substances like glucose for neuronal fuel, direct contact with
neural progenitor cells and the “tripartite synapse” in which astrocytes play a direct and
interactive role with neurons during synaptic activity and are critical for information processing
by neuronal circuits (Sofroniew & Vinters, 2010).
Here we report that significant changes in astrocyte morphology were observed in
animals that had undergone pilocarpine-induced SE, and that VEGF attenuated changes that
were reflective of size such as soma area, total volume and average diameter as well as process
branching and branching complexity. Overall, VEGF appeared to reduce the size and complexity
of the astrocytes and their processes and may therefore have resulted in a decrease in domain
organizational changes, metabolic disturbances, distribution changes or receptor function, or
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even alterations in astrocyte secretions or enzymes. Many questions remain about all the effects
VEGF could be having on the astrocytes that were not measured in this work. For instance,
another study from our lab suggested that VEGF reduces the level of glucose transporter (Glut-1
& 4) expression on brain vasculature adjacent to astrocytes (Scorpio et al., 2012). Furthermore,
animals that had undergone pilocarpine-induced seizures showed an increased level of glucose
transporter expression, perhaps in response to an increased metabolic load. This increase in
glucose transporters was accompanied by a decrease in glucose transport into the brain (Scorpio
et al., 2012). Therefore VEGF may protect neurons, in part, by reducing their oxidative
production and limiting glucose availability.
Astrocytes change following SE and reports show loss of organizational domains,
reactive gliosis, secretion changes, redistribution of AQP4, increased Na+ and Ca++ channels,
decreased Kir4.1 channels, reduced GS and lactate dehydrogenase as well as increased immune
molecules. Astrocytes showing these changes can be categorized into differing populations such
as strong GFAP reactive and weak GFAP reactive cells, where the weaker cells resemble GluR
astrocytes and are known as NG2+ cells. The functioning of these subtypes and or loss of one
type may lead to favored hyper-excitability and may trigger seizure spread even in a fairly
normal subiculum (Nobel, 2012). Work from the Nedergaard laboratory showed that reactive
astrocytes were increased in many types of seizure models and produced excessive glutamate
that could not be caused by neural firing as it was abolished. This group reported that reactive
astrocytes trigger epilepsy as opposed to the other way around (Tian et al., 2005) and suggested
there is a great need for treatments that do not slow down synaptic activity but rather control
glutamate release or inhibits reactive astrocytes. Other work from this lab proposes that
reorganization of astrocytes, along with dendritic sprouting and new synapse formation, may
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form the structural basis for recurrent excitation in the epileptic brain (Oberheim et al., 2008).
Finally, Tian and colleagues found robust gliosis may play a role due to imbalance of ionic
homeostasis, changes in volume that lead to neuronal hyper-synchrony and or by controlling the
synaptic strength between specific populations of neurons (Tian et al., 2005). The same group
found that intracellular Ca++ waves could facilitate seizures and can propagate therefore
resulting in long-range changes in excitation between neurons that were not synaptically
connected.
Together these findings propose an astrocytic basis for seizure generation and even for
recurrent seizures that may lead to circuitry that favors hyper-excitability. The current work
demonstrated changes in size and branching complexity in animals receiving pilocarpine-induced
SE and showed a significant effect of VEGF on attenuating these changes. Based on published
studies about the properties of reactive astrocytes, it seems likely that the astrocyte changes we
measured after SE in our experiments favored a reactive phenotype. As the measures of size and
complexity were significantly correlated with preserved behavioral function in the water maze,
this may suggest that the effect of VEGF was neuroprotective. This neuroprotection may have
been related to both preservation of astrocytic domain organization and metabolic rescue; both of
which could contribute to neuronal function.
Reactive Astrogliosis
Reactive astrocytes are reported to be important in the prevention of inflammation
spreading immediately following insult or injury. Additionally, reports show preventing reactive
astrocytes early on can prevent or slow recovery. For instance, Faulkner’s group showed that
ablating reactive astrocytes at an early time point prevented motor recovery in a model of spinal
cord injury (2004). Other studies have concluded that loss of astrocytes early on leads to
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secondary degeneration of other cell types (Lui et al., 1999; Zhao et al., 2003) due to
accumulation of extracellular glutamate causing excitotoxicity in neurons and oligodendrocytes
(Bush et al., 1999).
In spite of findings suggesting a beneficial contribution of reactive astrocytes
immediately after injury, reactive gliosis long-term may be detrimental to repair and recovery
following insult. Pekny and several colleagues (2004) have published data showing that reactive
gliosis can be beneficial immediately following insult or injury; and yet can be harmful to the
recovery of the system due to glial scarring and inhibited neurogenesis in adult animals. For
instance this group showed that mice deficient in two intermediate filament proteins, GFAP and
Vimentin, which are upregulated and thought of as hallmarks of reactive gliosis, exhibit
attenuation of reactive gliosis post-trauma. These same mice showed improved integration of
neural grafts as well as improved post-trauma regeneration in an ischemic model (Wilhelmsson
et al., 2004). These mice showed initial synaptic loss, but there was a complete synaptic
regeneration later on supporting the idea that reactive gliosis early on plays a beneficial role,
while prolonged gliosis causes problems in regeneration at a later stage. Pekny and colleagues
(2007) suggested that reactive astrocytes may be key targets for novel interventions.
Astrocytes & Glutamate Cycling
Astrocytic function is a key player in metabolism as neurons and astrocytes are coupled
in metabolism and the site of interaction for this coupling is at the synapse. Perhaps the most
important role for astrocytes at this site is the removal of K+ ions and glutamate, which
accumulate in the microenvironment during synaptic activity. Astrocytes provide the neurons
with glutamine and lactate needed for the rapid turnover of ionic gradients.
Astrocytes provide a cellular connection to neurons as well as providing a balance of
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excitation and inhibition. Astrocytes contribute to neurotransmission by regulating the
concentration of ions and neurotransmitters in the synaptic cleft, therefore influencing control
over synaptic efficacy (Barres, 2003). Gliotransmitters released by astrocytes may activate
receptors in neurons to modulate excitatory and inhibitory synaptic transmission and because
astrocytes can reach thousands of synapses simultaneously, this release may lead to
synchronization of neuronal firing patterns. Astrocyte dysfunction could also cause an
interruption or dysfunction in the glutamate-glutamine cycle, which is so crucial to the balance
of excitation and inhibition.
The first step in the astrocyte glutamate-glutamine cycle in astrocytic transport of
glutamate is uptake. This glutamate transport is crucial to proper neuronal functioning, and
deletion of genes that encode for these transporters results in glutamate-mediated excitotoxicity
(Rothstein et al., 1996). Astrocytes are responsible for up to 90% of glutamate uptake from the
extracellular space (Behrens et al., 2002) and pharmacological inhibition of the GLT-1 astrocyte
glutamate transporter reduces the threshold for epileptiform activity. GLT-1 alterations are
reported in many neurological disorders such as Huntington’s disease (Behrens et al., 2002, ALS
(Rothstein et al., 1996), Alzheimer’s disease (Masliah et al., 1996), ischemia (Torp et al., 1995),
and hippocampal sclerosis (Matthern et al., 1999). Furthermore, mice deficient in GLT-1 show
lethal spontaneous seizures (Tanaka et al., 1997).
Here we report that pilocarpine-treated animals had higher levels of GLT-1 expression in
the CA1 region of the hippocampus, but a decreased level of expression in the dentate region.
VEGF treatment did not alter this pattern. Perhaps clearance of glutamate was not as efficient in
the DG and the decreased level of expression is supportive of that; however in the CA1 area
GLT-1 was increased suggesting that the transporter levels may be sufficient for clearance of
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glutamate.
Glutamate transport is only the first step in the glutamate-glutamine cycle, so it would be
interesting to examine glutamine levels after pilocarpine-induced seizures in animals receiving
VEGF or inactive VEGF protein to determine if VEGF alters any other components of the
glutamate-glutamine cycle. Measuring the key enzymatic players in the cycle, GS or PAG,
could provide clues about any effect of VEGF on this biochemical process.
Astrocytes, VEGF & BBB
Although VEGF's effects on astrocytes could directly impact hippocampal circuit
function, it could also indirectly impact it via the important role of astrocytes in BBB integrity.
The BBB brings nutrients and mediates efflux of waste products by restricting both ionic and
fluid movement between the blood and brain. Astrocytes help by forming junctions with their
end feet as well as assisting in the formation of the BBB and maintaining ionic balance. Reports
also have found that the astrocyte precursor cells (APCs) are likely to induce endothelium
development, and that interactions of astrocyte lineage cells and endothelium progressively
generates the adult BBB (Barres et al., 2001). VEGF is a key player in driving vasculogenesis
and endothelial proliferation (Yancopoulos et al., 1998) and APC’s may express VEGF that
would drive these processes. In turn these endothelial cells would then drive the differentiation
of the APCs into astrocytes (2001) that would then trigger the formation of the BBB. Astrocytes
have direct contact with progenitor cells, endothelial cells and neighboring astrocytes. This view
opens interesting questions regarding the ability of these cells to stimulate differentiation or dedifferentiation under certain conditions to resolve the changes that would lead to further toxicity.
Given the responsibilities of astrocytes to maintain ionic balance it is possible that reactive
astrocytes are changed and no longer able to maintain the integrity of the BBB due to loss of
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cells and “neurovascular units”.
Leakage of the BBB is associated with many neurological disorders including temporal
lobe epilepsy. Work by Seiffert and colleagues (2004) suggest that focal opening or change in
BBB may be epileptogenic due to accumulation of albumin and therefore important in the
development of epilepsy disorders. Ivens (2007) showed that direct brain exposure to serum
albumin is associated with uptake into astrocytes mediated by TGF-ß receptors, and is followed
by downregulation of Kir 4.1 potassium channels which results in reduced spatial buffering of
extracellular potassium. The net effect of this alteration would be increased extracellular
potassium and NMDA receptor-mediated hyperexcitability.
The Relationship of Astrocyte Changes to Behavioral Preservation
In addition, to the observed alterations in astrocyte morphology, our study revealed
cognitive improvements in post-status animals treated with VEGF compared to animals
receiving Inactivated VEGF. Correlational matrices revealed that astrocyte morphology changes
in both size and complexity were predictors of the partial preservation of learning and memory.
This suggests that these measures have a relationship with the behavioral findings, but it is
important to note that this relationship is only correlational. No "cause and effect" statement can
be confidently asserted about the impact of astrocyte morphology on circuit function. It is,
however, possible that the preservation of a more normal astrocyte morphology in the VEGFtreated animals allowed for an increased ability for astrocytes to contribute to axon re-wrapping
and regeneration. That is, although neurons were lost equally in both seized groups (VEGF vs.
control), it is possible that that retention of normal astrocyte function allowed for the partial
preservation we observed in learning and memory due to better functional recovery of the
remaining neuronal circuit.
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Although earlier work from this lab found a full preservation of anxiety-related behaviors
in VEGF-treated animals, the current study did not find statistically significant effects of either
pilocarpine-induced seizures or VEGF treatment in the light/dark exploration task. Therefore, we
could not assess the recovery of normal emotional behaviors in our experiments.
Limitations & Future Directions
The current work had a number of limitations that represent opportunities for future work
to more fully interpret our findings. First, our study evaluated astrocyte morphology at only one
time point. It would be illuminating to evaluate a timeline in which VEGF was administered
right up to behavioral testing. Further, it would have been informative to be able to collect tissue
at different time points throughout the month after status to determine whether the changes in
astrocyte morphology observed one month after status were sustained throughout the post-status
period. Because of this limitation, it is difficult to fully evaluate whether VEGF was beneficial
or detrimental. That is, it is possible that the behavior was improved because VEGF was no
longer acting at the time of testing, and that it was VEGF withdrawal rather than VEGF
treatment that was protective. The goal of the current studies was to see if treatment with VEGF
around the time of status would result in long-lasting improvement without the need for chronic
VEGF treatment. Additionally, it may be revealing to investigate the age of the astrocytes using
markers such as glutathione transport or D-serine racemase which are only found in mature
astrocytes but not mature NG2+ cells or young astrocytes (Parpura & Haydon, 2009). This may
reveal more specific information regarding the astrocyte characteristics and VEGF effects. For
instance, it is possible that VEGF has different effects that are dependent upon the age of the
astrocyte or it could be that the astrocytes investigated were of different ages.
Given the finding of a possible alteration in Glt-1 levels with VEGF in CA1, future
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studies are warranted to address the astrocyte glutamate-glutamine cycle as well as to expand our
information about VEGF's potential effects on other aspects of the cycle such as GS and PAG.
Any impairment in these important parts of the cycle which regulate the glutamate levels and
provide neurons with glutamine could impact circuit function. This information could provide a
more complete picture of any disruptions or dysfunction in this important system in the balance
of excitation and inhibition.
One methodological limitation of this study was the use of GFAP to immunostain
astrocytes, which is now thought to only prominently stain a subset of astrocytes. In addition,
using this stain does not allow for the distinction between types of astrocytes nor does it allow us
to determine the age of astrocytes, a factor that is suspected to affect astrocyte function. The
heterogeneity of astrocytes may reveal the functional diversity of subtypes of astrocytes and their
particular interactions with other cell types may reveal important information regarding the
specific subtypes of astrocytes that contribute to the metabolism of neurotransmitters.
In addition to having multiple subtypes of astrocytes, the hippocampus is, of course,
invested in a wide variety of other cell types. The current study focused on astrocyte morphology
changes in seized and non-seized animals treated with either Inactivated VEGF or VEGFA165
protein. However, it is unlikely that VEGF only impacts astrocytes, and its impact on other cell
types in the brain could be equally or more important. VEGF could, for instance, impact
microglia or endothelial cells through their expression of VEGFR1 and other VEGF receptors.
Indeed, we can't rule out the possibility that VEGF's effects on astrocytes are themselves
indirect, occurring through intermediaries such as microglia, endothelial cells, or neurons. In
complex systems such as the brain, any impact of VEGF on one system has the potential to alter
others, and if that impact includes alterations in excitability, the net effect of that impact
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becomes even stronger within the context of epilepsy. Indeed, while our VEGF-treated animals
did not have statistically different seizure severity scores or latencies to seize, we have not
verified that post-status excitability is not altered at the circuit level by VEGF. It would be
important in future studies to use video-EEG technology during and after SE to allow for a more
refined measurement of seizure activity. If VEGF were found to cause alterations in excitability
after SE, which seems possible given prior work suggesting reduced excitability with VEGF
treatment (McCloskey et al., 2005), it might be expected to change any parameter that is
influenced by the excitability of the circuit. VEGF's promise as a potential seizure therapeutic is
unaltered by the results of such an investigation, but the interpretation of the mechanisms
underlying its beneficial effects could change.
Therapeutic Utility of VEGF in Epilepsy
More and more evidence is accumulating for astrocyte modulation as a target for clinical
therapeutic interventions. However, this approach requires the necessity to understand the
complex interactions between glial cells, neurons, progenitor cells and endothelial cells making
the research ahead vast. If VEGF does preserve the normal size and complexity of the astrocytes
and their processes, and allows for normal inter-astrocyte distance, it may facilitate the astrocytes
maintaining their organizational domains. It is possible that by preventing changes in astrocyte
size, complexity, and organization after seizures, VEGF may preserve the level of
thrombospondins or other growth factors, thereby contributing to the ability of the adult brain to
recover from the damaging consequences of seizure activity. VEGF itself is not likely to be a
viable therapeutic option for epilepsy because it is a large protein that does not cross the bloodbrain barrier. However, manipulating the VEGF pathway using other approaches could serve as
a future therapeutic for preventing the long-term sequelae of epilepsy. More research will be
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necessary to fully evaluate the potential of this pathway to be therapeutic in epilepsy.
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